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Abstract 
Global-scale examinations of biological systems at the molecular level complement targeted approaches 
to scientific inquiry that focus on specific subsets of biomolecules, or on a single molecule of interest. In 
this dissertation, we utilized both the discovery-based approach to evaluate the proteomics workflows 
centered around mass spectrometry as the key technology, and the targeted approach to examine the 
molecular response of RPE due to oxidized lipoproteins (oxLDL) treatments. A crucial aspect in 
proteomics studies is the design of bioanalytical strategies that maximize coverage of the complex 
repertoire of a proteome. A comprehensive, unbiased examination of the proteome represents a powerful 
approach toward system-level insights into disease mechanisms. We evaluated the performance of 
bioanalytical platforms for profiling of the proteome in a biological system. We applied a discovery-based 
approach to evaluate the global transcriptome and proteome changes due to oxLDL treatment in ARPE-19 
cells. 
We studied the role of scavenger receptors CD36 and CD5L/AIM in ARPE-19 cells when induced with 
oxLDL. We compared three different multidimensional proteome fractionation platforms: polymeric 
reversed-phase liquid chromatography at high pH (PLRP), sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), and isoelectric focusing (IEF) separations. We applied a liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) in a data-dependent setting and 
used bioinformatics for protein identification. The three platforms identified a total of 1043 proteins 
altogether. Among the three bioanalytical strategies, SDS-PAGE followed by LC-MS/MS provided the best 
coverage. We also evaluated another bioanalytical platform which consists of a highresolution mass 
spectrometer combined with nano-UPLC in a data-independent setting without pre-fractionation for oxLDL 
mediated proteome alteration in ARPE-19 cells. 
This platform outperformed the SDS-PAGE based analytical platform in terms of proteome coverage as it 
identified around 2500 proteins, ca. 3-fold more proteins than the latter. Most importantly, this platform 
was able to perform label free quantification of differentially expressed proteome alteration. The 
platforms identified proteins with diverse physicochemical characteristics involved in various functional 
roles within the biological system. 
Furthermore, we carried out the first comparative transcriptomic and proteomic study for the evaluation 
of oxLDL effects on ARPE-19 cells after a 4 h exposure. The treatment with oxLDL affected the regulation 
of more than 700 genes that were involved in regulation of cell cycle, oxidative stress, cholesterol efflux, 
circadian rhythm, NRF-2 pathways. However, LDL treatment alone did not induce the regulation of these 
pathways. The differential proteomic analysis found 41 proteins affected due to the oxLDL treatment. 
This study provided a foundation for a bioanalytical platform for identification and label-free 
quantification in the human retinal pigment epithelial cells (ARPE-19) proteome. The list of differentially 
expressed proteins due to oxLDL treatment identified in this study gives insights to the change in proteins 
that might be interrogated for their roles in pathogenesis of macular degeneration. These findings could 
give us targets to intervene in the pathogenesis of AMD progression in human for the development of 
better treatment and prevention against this degenerative disease. 
Lastly, we studied the mechanistic role of scavenger receptors CD36 and CD5L/AIM in oxLDL uptake by 
ARPE-19 cells. We, for the first time, demonstrated the presence of scavenger receptor CD5L in ARPE-19 
cell. The oxLDL uptake was primarily dependent on CD36, and both the CD5L/AIM and CD36 were seen to 
co-localize in the presence of oxLDL. Our results suggest a new dynamics on CD5L/AIM on the oxLDL 
uptake that was not seen in macrophages. The reduction in intracellular accumulation of oxLDL in the 
presence of extracellular recombinant CD5L/AIM is an interesting phenomenon as it has been recently 
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 Global-scale examinations of biological systems at the molecular level 
complement targeted approaches to scientific inquiry that focus on specific subsets of 
biomolecules, or on a single molecule of interest. In this dissertation, we utilized both the 
discovery-based approach to evaluate the proteomics workflows centered around mass 
spectrometry as the key technology, and the targeted approach to examine the molecular 
response of RPE due to oxidized lipoproteins (oxLDL) treatments. A crucial aspect in 
proteomics studies is the design of bioanalytical strategies that maximize coverage of the 
complex repertoire of a proteome. A comprehensive, unbiased examination of the 
proteome represents a powerful approach toward system-level insights into disease 
mechanisms. We evaluated the performance of bioanalytical platforms for profiling of the 
proteome in a biological system. We applied a discovery-based approach to evaluate the 
global transcriptome and proteome changes due to oxLDL treatment in ARPE-19 cells. 
We studied the role of scavenger receptors CD36 and CD5L/AIM in ARPE-19 cells 
when induced with oxLDL.  
 
 We compared three different multidimensional proteome fractionation platforms: 
polymeric reversed-phase liquid chromatography at high pH (PLRP), sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and isoelectric focusing (IEF) 
separations. We applied a liquid chromatography-mass spectrometry/mass spectrometry 
(LC-MS/MS) in a data-dependent setting and used bioinformatics for protein 
identification. The three platforms identified a total of 1043 proteins altogether. Among 
the three bioanalytical strategies, SDS-PAGE followed by LC-MS/MS provided the best 
coverage. We also evaluated another bioanalytical platform which consists of a high-
resolution mass spectrometer combined with nano-UPLC in a data-independent setting 
without pre-fractionation for oxLDL mediated proteome alteration in ARPE-19 cells. 
This platform outperformed the SDS-PAGE based analytical platform in terms of 
proteome coverage as it identified around 2500 proteins, ca. 3-fold more proteins than the 
latter. Most importantly, this platform was able to perform label free quantification of 
differentially expressed proteome alteration. The platforms identified proteins with 
diverse physicochemical characteristics involved in various functional roles within the 
biological system. 
 
 Furthermore, we carried out the first comparative transcriptomic and proteomic 
study for the evaluation of oxLDL effects on ARPE-19 cells after a 4 h exposure. The 
treatment with oxLDL affected the regulation of more than 700 genes that were involved 
in regulation of cell cycle, oxidative stress, cholesterol efflux, circadian rhythm, NRF-2 
pathways. However, LDL treatment alone did not induce the regulation of these 
pathways. The differential proteomic analysis found 41 proteins affected due to the 
oxLDL treatment. This study provided a foundation for a bioanalytical platform for 
identification and label-free quantification in the human retinal pigment epithelial cells 
(ARPE-19) proteome. The list of differentially expressed proteins due to oxLDL 
treatment identified in this study gives insights to the change in proteins that might be 
interrogated for their roles in pathogenesis of macular degeneration. These findings could 
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give us targets to intervene in the pathogenesis of AMD progression in human for the 
development of better treatment and prevention against this degenerative disease. 
 
 Lastly, we studied the mechanistic role of scavenger receptors CD36 and 
CD5L/AIM in oxLDL uptake by ARPE-19 cells. We, for the first time, demonstrated the 
presence of scavenger receptor CD5L in ARPE-19 cell. The oxLDL uptake was primarily 
dependent on CD36, and both the CD5L/AIM and CD36 were seen to co-localize in the 
presence of oxLDL. Our results suggest a new dynamics on CD5L/AIM on the oxLDL 
uptake that was not seen in macrophages. The reduction in intracellular accumulation of 
oxLDL in the presence of extracellular recombinant CD5L/AIM is an interesting 
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CHAPTER 1.    INTRODUCTION 
 
 
 Global-scale examinations of biological systems at the molecular level 
complement targeted approaches to scientific inquiry that focus on specific subsets of 
biomolecules, for example components of a molecular pathways, or on a single molecule 
of interest such as a specific protein. The long-term research focus of our laboratory has 
been centered on proteomics. Research activities encompass development and 
optimization of bioanalytical workflows for proteomics as well as application of 
proteomics in various contexts including investigation of disease mechanisms and to 
discovery of new biomarkers. Proteomics is the large-scale study of structure and 
function of all the proteome, where proteome is defined as a set of proteins present in any 
biological system under a given condition. It provides a global insight into the abundance 
of protein expression, its localization, and interaction. Recent development of advanced 
proteomics tools has allowed scientists to perform large-scale, high throughput screening, 
detection, identification and analysis of proteins in a complex biological system. 
Moreover, advances in mass spectrometric based proteomic techniques, along with 
protein fractionation and labeling techniques have allowed identification of less abundant 
proteins and post translational modification in the proteins possible. These developments 
and improvements in proteomic techniques have significantly contributed to elucidate 
various signaling networks, dynamics of protein-protein interactions and molecular 
understanding of disease mechanism. However, the global scale examination of a 
proteome is extremely challenging due to the unavailability of a single analytical 
platform capable of handling the diversity and extent of proteome complexity. For 
instance, if we want to investigate potential biomarker in plasma of patients with macular 
degeneration, the human biological fluid has few highly abundant proteins which make it 
difficult to identify the low abundant proteins present in the same sample. As a single 
analytical platform that is capable of analyzing a complete proteome map of cells or 
tissues is not available to date, multiple bioanalytical approaches coupled together can be 
used to achieve maximum coverage of entire proteome in a system. The combination of 
the approaches and their configuration depends on the samples, resources, time and 
desired outcome.  
 
 A typical workflow in mass spectrometry based proteomic analysis consists of 
three blocks: the separation techniques, the mass spectrometer, and the bioinformatics 
tools. Multi-dimensional chromatography and/or electrophoretic techniques are used to 
pre-fractionate highly complex proteomes, to reduce their complexity, followed by liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analysis. The 
output from mass spectrometry is then analyzed using bioinformatics tools. 
 
 Age-related macular degeneration (AMD), as its name suggests, is a disease of the 
elderly. It is one of the leading causes of blindness in elderly in developed countries [1]. 
AMD is the degeneration of macula which is responsible for the central vision that 
enables us to drive and read. It can be broadly divided into two forms; dry AMD and wet 
AMD. Dry AMD affects a larger population, accounting for around 90% of total AMD. 
The disease is caused when drusen start accumulating in the macula between retinal 
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pigment epithelium (RPE) and the Bruch’s membrane. RPE is primarily responsible for 
clearing the damaged photoreceptors by phagocytosis. In the older population, the 
reduced capacity of RPE to clear the debris causing atrophy of the retina leads to the loss 
of vision. In contrast, wet AMD is caused due to the growth of the abnormal blood vessel 
in the macula causing vision loss. 
 
 There are few treatments available for wet AMD, but no FDA approved drug is 
available till date to treat dry AMD. Some of the FDA approved drugs for wet AMD and 
drugs that are under investigation are listed in Table 1-1. This has enticed the scientific 
community towards the understanding of the disease progression of dry AMD at the 
molecular level. Some studies have suggested that the inflammation and activation of the 
innate immune system are involved in the advancement of AMD. However, the 
molecular mechanism to explain the complex etiology of AMD including RPE cell death, 
damage due to oxidative stress, mitochondrial dysfunction and the accumulation of toxic 
components such as lipofuscin and other oxidative damaged product still needs to be 
interrogated to develop targeted therapies for AMD.  
 
 The retinal pigment epithelium (RPE) is one of the most important part of the 
human eye that affected due to AMD. RPE is a hexagonal, pigmented monolayer. It is 
tightly packed with the tight junction and adherens junction proteins and forms an 
integral part of the outer blood retinal barrier (BRB) (Figure 1-1A). The RPE layer in the 
human eye is located between the photoreceptor, which is prone to light induced 
oxidative stress, and the choroid that has a high supply of oxygen (Figure 1-1B) [2]. 
 
 Oxidative stress has long been hypothesized to contribute to the pathogenesis and 
progression of AMD. The lipids in the RPE originate primarily from the photoreceptors 
that are phagocytosed and are eliminated via the choroid. When we age, the RPE 
deteriorates in its functions leading to the accumulation of the lipids like 
docosahexaenoic acid (DHA, a primary component of photoreceptor outer segments) in 
the Bruch’s Membrane (BM). Over time, these are modified into harmful oxidized 
lipoprotein (oxLDL) products, a component of drusen [3]. It is believed that reduced 
capabilities to absorb light and to compensate for oxidative damage are important factors 
that initiate the chain of events leading to the onset of AMD in the older population [2, 4, 
5]. 
 
 Oxidized lipoprotein formation within the eye is a complex process where both 
lipids and proteins of the LDL molecule are oxidized. The oxidation of LDL is supposed 
to be modified in a stepwise method. In the initial phase of modification, the lipid portion 
of the lipoprotein gets oxidized when they react with the oxidizing agents. This is 
followed by the reaction of lipid oxidation products with the apoB protein moiety of the 
LDL resulting in the oxidative change in the amino acid side chain forming the 
oxLDL[6]. Understanding the mechanisms for the fate of oxLDL within the RPE cells 
and the change in transcriptome and proteome of the RPE cells due to oxLDL would 
elucidate the molecular events in the pathogenesis of AMD. This would decipher the role 
of oxidative stress due to oxLDL to provide new opportunities for better treatment and 
prevention of the disease.  
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Table 1-1. List of FDA approved/investigational drugs for dry and wet AMD. 
 
Drug/Device Time Dry vs Wet AMD Company Mechanism of Action  
Approved      
 Implantable telescope Jul-10 End-stage AMD VisionCare 
Ophthalmic 
Technologies 
It magnifies the overall 
image while reducing the 





Jun-06 Advanced or "wet" 






It inhibits vascular 
endothelial growth factor 
(VEGF) 
 
 Macugen (pegaptanib 
sodium injection) 
Advanced or "wet" 




It contains pegaptanib ,a 
selective vascular 
endothelial growth factor 
(VEGF) antagonist 
 
 Eylea (aflibercept) Nov-11 Advanced or "wet" 






It is an anti–vascular 
endothelial growth factor 
(anti-VEGF) treatment 
 
 Visudyne drug 
treatment 
(Photodynamic 
Therapy or PDT) 
Wet form of macular 
degeneration 
Novartis It uses photodynamic 
therapy (PDT)  that destroys 
abnormal blood vessels. 
 
 Laser treatment Wet AMD photocoagulation  
Investigational      
 Eylea and antibody 
combination therapy 
Regeneron   
 Avastin 
(bevacizumab) 
Genentech.   
 OHR-102. Nov-15 Wet AMD Ohr 
Pharmaceutical. 
  
 MC-1101 2012, phase 3 
testing of the 
drug therapy 
Prevent dry AMD to 
progressing to wet 
AMD 
MacuCLEAR increases blood flow to the 
choroid 
 
Drug Implants   
 Ranibizumab PDS 2012 Wet AMD Genentech It inhibits vascular 
endothelial growth factor 
(VEGF) 
 





Implant that contains 
genetically modified human 
cells capable of secreting a 
nerve growth factor that 
rescues and protect dying 
photoreceptors in the retina 
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Table 1-1. (Continued.)  
  
 Drug/Device Time Dry vs Wet AMD Company Mechanism of Action  
Artificial Retinas   
Artificial Silicon 
Retina (ASR) 
Optobionics It is a microchip that 
stimulates healthy retinal 
cells to restore vision 
 
Stem Cells   








 June 2015/ 
phase 1/2 
clinical trial 














Figure 1-1. RPE structure and location. 
(A) Hexagonal structure of cultured human retinal pigment epithelial cells (ARPE-19) 





 As AMD is one of the leading causes of blindness in elderly people and with the 
lack of the complete knowledge on disease progression, it will continue to affect a large 
population. The facts that there is no available treatment for dry AMD and that the 
treatments for wet AMD are not showing the desired outcomes, there is an immense and 
immediate need of understanding the molecular mechanism of the pathogenesis and 
progression of the disease. The differential proteomic analyses of the eye affected with 
AMD and a normal eye will definitely provide a great insight into the protein expression 
patterns. These lead to a path towards the discovery of a drug to treat, cure or reverse the 
disease and helps to improve the quality of life of patients living with AMD.  
 
 
Dissertation Hypothesis and Specific Aims 
 
 The research presented in this dissertation encompasses two major components. 
(1) The first component is the bioanalytical component that focuses on evaluation of 
proteomics workflows centered around mass spectrometry as the key technology. As 
stated in the following statement by J. Van Eyk, “the diversity and extent of proteome 
complexity will not and cannot be solved by a single technology”, global scale 
examination of proteome is extremely challenging. Hence, a reliable and robust analytical 
method to study the proteome of a biological system needs to be established which can 
eventually provide a foundation to study the proteome perturbation due to oxLDL 
treatment in the ARPE-19 cells. The hypothesis for this component is that fractionation of 
the proteome at the protein or peptide level prior to LC-MS/MS analysis increases the 
number of identified proteins and enhances access to low abundance proteins.  (2) The 
second component of my research focuses on application of global-scale and targeted 
approaches to examination of the molecular response of retinal pigment epithelium (RPE) 
cells to oxidized lipoproteins. The central hypothesis for this component is that oxidized 
low density lipoprotein (oxLDL) is internalized by the RPE cells through the action of 
scavenger receptors CD36 and CD5L/AIM, and induces a cytoprotective molecular 
response in the RPE cells. 
 
 
Aim 1. To Evaluate the Capabilities of Bioanalytical Platforms in Terms of Extent 
and Depth of Proteome Coverage 
 
 In recent years, major advancements in the area of mass spectrometry have 
contributed to a shift from use of proteomics workflows that were based on 2D gel 
electrophoresis to alternative workflows that incorporate powerful tandem mass 
spectrometry technologies, often in combination with up-stream fractionation at the 
protein and/or peptide level. With any proteomic technique, there is a bias towards more 
abundant proteins. Multiple analytical techniques are required to study the entire 
proteome of a biological system which depends upon the desired outcome, sample, 
resources and time. Three bioanalytical platforms will be analyzed to characterize 
mitochondrial proteome. The main objective of this aim is to evaluate the capabilities of 




Aim 2. To Determine the Roles of Scavenger Receptors CD36 and CD5L/AIM in the 
Clearance of OxLDL by the Human Retinal Pigment Epithelial Cells 
 
 Accumulation of oxidized lipoproteins (oxLDL) in the eye is considered as an 
important trigger in the pathogenesis of AMD. OxLDL are identified by special receptors 
in cells known as scavenger receptors. To better understand the role of two scavenger 
receptors in clearance of oxLDL in the eye we postulated following hypothesis based 
upon our central hypothesis: i) we hypothesize that the transmembrane scavenger 
receptor CD36 binds oxLDL on the surface of RPE cells and mediates oxLDL uptake by 
the cells; ii) we hypothesize that the RPE cells express and secrete the soluble scavenger 
receptor CD5L/AIM. We further postulate that CD5L/AIM present in the extracellular 
space binds oxLDL and facilitates its clearance by the RPE cells.  As an in vitro model of 
the RPE, we will use the well-established ARPE-19 cell line. We will investigate the role 
of CD36 and CD5L/AIM involvement in uptake of oxLDL by ARPE-19 cells and the 
molecular effect of this uptake. 
 
 
Aim 3. To Characterize OxLDL-induced Molecular Response in the RPE Cells 
 
 Our working hypothesis is that the uptake of oxLDL by the ARPE-19 cells 
induces a cytoprotective molecular response. We postulate that this molecular response 
will be multifaceted and involve alterations of diverse pathways and networks. To fully 
capture this response, we will use global-scale, discovery-based approaches to 





 In chapter 2 of my dissertation, I investigated on the aim 1 i.e. bioanalytical 
component of my dissertation. The main objective of this aim was to evaluate the 
capabilities of three different bioanalytical platforms in terms of extent and depth of 
proteome coverage. When performed before LC-MS/MS analysis, it provided better 
extent and in-depth proteome coverage. In chapter 3, I investigated aim 2 i.e. the 
scavenger receptors that are involved in the transport of oxLDL. I described the effect of 
oxLDL treatment and the mechanistic understanding gained from the results after the 
treatment on ARPE-19 cells. In chapter 4 and 5, I explored, aim 3 of my dissertation. In 
chapter 4, I examined the transcriptome alteration in ARPE-19 cells due to oxLDL and 
LDL treatments. The main objective of this study was to understand oxLDL induced 
alterations in various mechanistic pathways potentially related to AMD pathogenesis. In 
chapter 5, I assessed the proteomic alteration in ARPE-19 cells after oxLDL and LDL 







CHAPTER 2.    PROTEOMICS IN BIOLOGICAL SYSTEM: STUDY OF 





 Proteomics, as coined by Marc Wilkins and colleagues during the early 1990s, is 
the large-scale study of the proteome, i.e. a set of proteins present in a biological system 
under a given set of conditions [7]. The accomplishments of the human genome project 
that annotated the human genome have steered the identification of over twenty thousand 
protein coding genes [8]. Besides the genetic instructions encoded in the genome, the 
knowledge of the proteins involved is equally vital to understand the biological processes 
that include synthetic, catalytic and regulatory functions occurring inside a living cell [9]. 
Proteins are the fundamental players in nearly all the biological processes that are 
concurrently active in every living cells working in a very coordinated fashion [10]. 
  
 The analysis of proteins in a particular system is difficult due to unavailability of 
tools that can efficiently analyze the whole proteins in biological systems, unlike the gene 
expression measurement which has a long history of well characterized tools [11]. Many 
proteins, produced by specific genes, undergo different posttranslational modifications. In 
addition, the variety and extent of posttranslational modifications of these proteins vary 
due to different environmental conditions within and outside the cells [12]. Thus, 
elucidating the structure and function of proteins in a proteome along with the 
understanding of their dynamic interaction with other inter- and intracellular proteins and 
components are the major challenges in protein biology [13]. 
 
 
Mass Spectrometry Based Proteomics  
 
 Proteomics is a widely used strategy in the field of biology. Proteomic approaches 
are applied for proteome profiling, identification and localizing of posttranslational 
modification within the protein, and the study of protein-protein interactions [14]. There 
are various techniques that can analyze different aspects of protein structure and function 
such as protein arrays, analytical microarrays, functional protein microarrays, high-
throughput protein hybridization and crystallization, analytical and reverse phase 
microarrays [15]. However, mass spectrometry has emerged as the most prominent 
strategy used at present for global-scale analysis of proteins in complex biological 
systems. The early methods for protein sequencing included Edman degradation in which 
proteins were sequenced by chemically cleaving the amino acids one at a time from the 
N-terminus. It required a high level of expertise, and therefore it could not be applied to 
all the protein sequencing, for example, if the N-terminus were chemically modified, this 
process would not work [9]. By late-1990, the Edman degradation technique was 
                                                 
 
1 Reprinted with open access permission. Giorgianni, F. Koirala D, Weber T. Giorgianni-Beranova S., 
Proteome analysis of subsarcolemmal cardiomyocyte mitochondria: a comparison of different analytical 
platforms. Int J Mol Sci, 2014. 15(6): p. 9285-301.(19) 
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gradually replaced by mass spectrometry based strategies. In the last two decades, mass 
spectrometry based techniques have profoundly influenced proteomics research. They 
have become dominant analytical techniques not only in large-scale ‘proteomic' studies 
but also in mechanistic and hypothesis driven studies, to successfully identify and 
quantify a single component of a proteome [16-18]. 
 
 Global scale examination of the proteome is still extremely challenging, as a 
single protein encoded by a gene may have multiple isoforms with different functions. 
Moreover, the protein may be modified by post-translational modifications or may be 
involved in interactions with other proteins within the cell. In addition, the mammalian 
cells, tissues, and body fluids display a complex mixture of a wide range of protein 
concentrations. Therefore, no single analytical platform is capable of solving the diversity 
and extent of proteome complexity [19]. Even with the development of various 
separation techniques, the advancement in mass spectrometers, and the improvement of 
computational bio-informatics tools, many important analytical needs still remain to be 
fulfilled. Among such limitations is the ability to analyze complex biological mixture and 
to identify and quantify low abundant proteins present in complex protein mixtures. 
These issues can be addressed by effective separation techniques, state-of-art mass 
spectrometry instruments and efficient data processing and analyzing computational tools 
[14]. 
 
 Based on the characterization of peptides or proteins by mass spectrometry, the 
field of proteomics can be divided, in general, into two main analytical approaches: top-
down and bottom-up. The top-down proteomic approach focuses on the analysis of intact 
proteins without proteolytic digestion [20]. In the bottom-up proteomic approach, on the 
other hand, proteins in a sample are first digested by a proteolytic enzyme to generate 
peptides. Analytical data diagnostic of the peptide sequences are then obtained by mass 
spectrometry, commonly after fractionation of the peptide mixture by liquid 
chromatography. The sequence-diagnostic information obtained from the mass 
spectrometer for the m/z of the peptides and their respective fragments are then compared 
to the in-silico data from a protein sequence database to identify the protein [21]. Bottom-
up proteomics is at present the most widely used approach. 
 
 
Components of Mass Spectrometry Based Bioanalytical Proteomic Workflow 
 
 In general, typical bioanalytical workflows for bottom-up proteomics comprise of 
three main components (Figure 2-1): i) Sample preparation ii) Protein and/or peptide 
separation and iii) Protein identification/quantification, interpretation and data analysis. 
There are many variations within the elements of this generic workflow. 
 
 Sample preparation. To study the proteome in a given biological sample, the 
first and critical step is the extraction of proteins. For the proteomic analysis, the 











the other biological materials such as lipids and nucleic acid [22]. Sample preparation 
techniques differ depending upon the starting sample material and purpose of the 
experiment. In general, for cells and tissues, the samples are first homogenized, 
sonicated, pulverized or disrupted. In contrast, for biological fluids, the samples are first 
depleted [23]. The protein can then be extracted with the aid of detergents (SDS, CHAPS, 
cholate, Tween), reducing agents (DTT, mercaptoethanol, thiourea), denaturing agents 
and enzymes. Protease inhibitors are commonly used to prevent proteolytic protein 
digestion. A number of methods have been developed by using the above mentioned 
agents in different combinations. However, care should be taken if some of the above 
mentioned agents interfere with the downstream proteomic analysis by a mass 
spectrometer.  
 
 Protein/peptide separation. Since the analysis of complex protein mixture is 
difficult, it is very important to consider separation of the proteins and/or peptides before 
mass spectrometry analysis. Separation of a complex protein and/or peptide mixture can 
be done by either gel-based or gel-free methods, and various separation methods have 
been incorporated in proteomics workflows. Selected methods used for this purpose are 
discussed in more detail below. 
 
 Separation at protein level: Gel electrophoresis. Gel electrophoresis is widely 
used in proteomics to separate proteins. After the rise of proteomics in the 1990s, two-
dimensional (2D) gel electrophoresis had been an integral component of most original 
proteomics workflows, and a method of choice for relative protein quantification in 
differential protein expression studies [24]. Advancement of powerful tandem mass 
spectrometry instrumentation and associated bioinformatics tools caused a departure from 
2D gel electrophoresis-based workflows in recent years. In two-dimensional gel 
electrophoresis, the proteins first undergo separation by isoelectric focusing (IEF) based 
on the net charge of the protein and then the charge-separated proteins are separated in 
the second dimension according to their molecular weight by SDS-PAGE [25]. 2D gel 
electrophoresis has a very high resolving power as thousands of proteins can be separated 
in a single gel. 2D separation provides high information content on each separated protein 
as each protein is characterized by its pI and molecular weight and when analyzed by 
mass spectrometry after 2D separation protein identity can be known. This method can 
also effectively separate individual modified protein forms which are very important for 
identifying the posttranslational modification of proteins [25]. However, this technique is 
very labor intensive as it requires a lot of time and effort to gel fractionation, protein 
extraction and peptide digestion [26]. Also, the sensitivity of 2D gel electrophoresis 
depends upon staining method [27], and only a fraction of proteome can be revealed in a 
single 2D gel [14]. 
 
 Besides SDS-PAGE based protein separation, an analogous strategy is the one-
dimensional gel-based proteomic strategy that uses in-gel IEF separation at protein level 
combined with down-stream LC-MS/MS. This workflow was first introduced by our 
laboratory and applied analyze the proteome in the human pituitary and human prostate 
cancer tissue [32, 33]. This method has also been successfully used for phosphoproteome 
discovery in the pituitary and prostate [33-35]. Iso-electric focusing is a high resolution 
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separation technique which separates proteins according to their isoelectric points (pI) 
within a continuous pH gradient. Immobilized pH gradient (IPG) strips are commercially 
available and are used to separate the proteins according to their pI. The IPG strips with 
wide pH gradient pH 3-10 are often used for whole proteome analysis [36]. Proteins are 
amphoteric in nature which means that they contain both acidic and basic groups and 
carry a charge depending on the pH of the surroundings. Since proteins are negatively 
charged in solution at pH above the pI and positively charged below the pI, a protein, 
during electrophoresis, will migrate towards cathode if it has positive net charge in a pH 
region below its pI. Similarly, at pH values above its pI, the negatively charged protein 
molecules will move towards the anode. Thus the protein molecules move in the electric 
field until they reach the pH region that corresponds to the protein pI, where they focus 
into sharp bands.  For comprehensive proteome analysis, following IEF separation, the 
entire IPG strip is sectioned and the proteins in each section are digested. The peptide 
digests from each section are subjected to LC-MS/MS to obtain sequence-determining 
data for peptide and protein identification.  
 
 Separation at peptide level: Gel free separation. A collection of gel free 
strategies for separation of complex mixtures in proteomics has been developed, which 
utilize a combination of liquid chromatography methods with different chemistries. 
Among these gel free methods, multidimensional protein identification technology 
(MudPIT) is a very popular two dimensional liquid chromatography (2D-LC) analytical 
workflow which is a widely accepted method for analysis of proteomes from a wide 
variety of samples [37]. MudPIT is also known as shot gun proteomics. In MudPIT, a 
whole proteome is first digested, and the highly complex peptide mixture is loaded 
directly into a microcapillary column packed with strong cation exchange (SCX) in the 
first dimension which is coupled to reverse phase (RP) column in the second dimension. 
The coupling of SCX and RP can be either offline or online, with the second dimension 
(RP) comprising the LC component of LC-MS/MS. The two dimensional separation 
gives better coverage of identified proteins than 2D gel electrophoresis method due to the 
difference in selectivity of peptides by SCX and RP. In addition, there is good 
compatibility between the SCX mobile phase and second dimensional RP separation. 
However, like any other methods, MudPIT has some disadvantages. For instance, the 
proteins are digested before separation makes the identification of isoforms difficult [38-
40].  
 
 An alternative method for MudPIT has been developed that utilizes the RP 
column in both the dimensions is known as reverse phase reverse phase separation (RP-
RP) method. In a study that explored the RP column for separation of peptides in both 
dimensions found that the mobile phages had a significant impact in RP selectivity and 
selection. This study showed that the use of mobile phases with different pH, particularly 
pH 10 on the first dimension and pH 2.6 on the second dimension, for a system with C18 
column provided the optimum orthogonality [41]. The RP-RP method permitted the 
collection of multiple fractions with minimal overlap in the first separation resulting no 
peptide losses as well as better recovery of both long and short peptides [42]. Various 
studies have however demonstrated the better performance of PLRP-based approaches in 
2D LC-MS/MS applications for shotgun proteomic studies compared to the MudPIT 
 
13 
platform. PLRP based approach is a slight modification in the RP–RP method, using 
polymer-based reversed-phase (PLRP) column and high-pH mobile phase is used in the 
first dimension, followed by conventional C18 reversed-phase separation at low pH [43, 
44]. 
 
 Liquid chromatography and mass spectrometry. The complex mixture of 
peptides in bottom-up proteomics workflows that are obtained either by fractionation or 
without fractionation are separated by RP liquid chromatography before MS and MS/MS 
analysis. The use of Ultra High Performance Liquid Chromatography (UPLC) as an 
analytical technique for the separation of peptides has drastically increased the efficiency. 
As a result, it is an integral part of peptide/protein identification by mass spectrometry. In 
recent years, HPLC/UPLC has experienced substantial developments and new separation 
combinations of different stationary phases or the use of various mobile phases. 
However, the reversed phase chromatography (RPC) is one of the widely used techniques 
for the separation of proteins and peptides. The separation of tryptically digested peptides 
in proteomics research using RPC is based on the interaction of sample analytes with the 
hydrophobic stationary phase. Nano-LC is another very important and most commonly 
used tool for separating the peptides/proteins before mass spectrometry analysis. The 
main advantage of using the nano capillary LC is to enhance the sensitivity caused by the 
reduced radial dilution in a narrow column [45]. The use of nano-UPLC as a novel 
analytical technique is capable of using chromatography resins with diameter less than 
2μm. It can, therefore, overcome problems regarding high pressure, improving the 
resolution, sensitivity and speed. 
 Mass spectrometry is a powerful analytical technique used to identify and 
quantify unknown compounds, biomolecules, proteins, and peptides. It measures the ratio 
between the mass and charge of ions which gives various information on proteins 
regarding their identity, chemical modification, and structure. Recent advances in the 
field of mass spectrometry have been one of the major driving force in the field of 
proteomics. Mass spectrometer mainly consists of three different parts: (i) ion source (ii) 
mass analyzer and (iii) detector. The ion source converts analytes into gas phase ions as 
they must be charged in the gas phase to be analyzed by mass spectrometer. The charged 
ions are then separated by the analyzer on the basis of their mass-to-charge ratio. Finally, 
the ions resolved by the analyzer are detected by a detector which will amplify the 
response to give a measurable response [46]. 
 The Nobel Prize awarded to two scientists Dr. John Fenn and Dr. Koichi Tanaka 
in 2002 for the development of two ionization techniques signifies the importance of 
ionization in mass spectrometry based techniques. The development of two ionization 
techniques MALDI (matrix-assisted laser desorption ionization) and ESI (electrospray 
ionization) revolutionized the protein identification by mass spectrometry. These 
ionization methods allowed the vaporization and ionization of large nonvolatile proteins 
and peptides molecules which were not achieved by the earlier ionization methods such 




 MALDI ionization method uses laser energy absorbing matrix which creates ions 
from large molecules that usually produces singly charged ions[48]. The protein samples 
are mixed with an appropriate solvent and are allowed to crystallize. So when this 
mixture is irradiated by laser energy, the analyte in gas phase is carried into the mass 
spectrometer. MALDI, however, has few drawbacks. It has a high preference to ionize 
basic peptide as it preferentially ionizes arginine containing peptide in a tryptic peptide 
mix. Due to the same reason, it poorly ionizes the phosphopeptides as the phosphate 
group possesses acidic properties [49]. 
 
 The electrospray ionization is another most widely used technique for ionization. 
The liquid sample solution is directly converted into gas phase ionized molecules in the 
presence of a strong electric field which aids on-line coupling of HPLC with ESI based 
mass spectrometer [50]. This results in multiple charged analyte ions which are desirable 
for proteomics as the higher molecular weight compounds could be easily analyzed by a 
mass spectrometer with low mass range. One of the main advantages of ESI is that it 
produces multiple charged molecules/ions and can be easily coupled with HPLC [51].  
 
 Along with the development of ionization techniques, improvements in mass 
analyzers also aided the revolution of mass spectrometry based proteomics. Mass 
analyzer measures gas phase ions with respect to their mass-to-charge ratio (m/z). The 
popular mass analyzers in the field of proteomics are linear ion trap, orbitrap, and QTOF.  
 
 Linear ion trap mass spectrometer stand alone has been for a number of years the 
prominent configuration and workhorse of global proteomics [52]. The linear ion trap 
mass analyzer consists of a set of quadrupole rods that confines ions radially with radio 
frequency (RF) and a static electric potential on end to confine the ions axially. It can trap 
ions with different m/z values over a period and eject sequentially into the detector. Ion 
traps collect, store and eject the ions and these activities cycle through many rounds. In 
each round, ion traps can isolate and fragment peptide ions. In the field of proteomics, 
linear ion traps, quadrupoles, orbitraps, and time of flight (TOF) are the commonly used 
mass analyzers. Each analyzer has its own specific characteristics. These analyzers either 
alone or in combination as a component of hybrid mass analyzers are being continuously 
developed or improved for better proteomic applications. 
 
 The analytes are acquired in different ways by a mass spectrometer. The data-
dependent acquisition (DDA) is one of the preferred methods for discovery-based 
proteomics where each full MS scan is followed by a specific number of MS/MS scans. 
Since its inception around the 1990s, the DDA continues to dominate the field of 
proteomics as a preferred method for deciphering the information from a complex 
mixture of peptides. With the complex samples (i.e., complex peptide mixture) a large 
number of compounds elute from the nano-LC column in a given instant. The DDA 
method first acquires the full spectrum of peptides (the MS spectra) of the ions that co-
elute from LC [10]. The mass spectrometer then selects a pre-defined precursor in real 
time (usually the most abundant one). It then acquires the fragment ion-spectra for the 
selected precursor ions. The mass spectrometer instrument runs in iterative acquisition 
cycle first to select the precursor ion spectra, i.e. (MS or MS1), and then the fragment ion 
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spectra (MS/MS or MS2). The instrument then puts a mass into an exclusion list 
(Dynamic exclusion principle) after its MS/MS scan is acquired so that the peptides that 
co-elute with high abundant peptides have chances of detection by the mass spectrometer. 
The instrument hence selects the most abundant ions for further MS/MS scans and hence 
the analytes that show the strongest signals have highest chance to be successfully 
identified.  Although DDA has been used as an ultimate data acquisition method in the 
field of proteomics, it only samples peptides with restricted dynamic range. This is 
because the precursor ion selection method in the DDA is designed in such a way that it 
only selects the most abundant ions [53]. An example of DDA by LTQ ion trap mass 
spectrometer is shown in Figure 2-2.  
 
 Another emerging data acquisition method in the field of proteomics is data 
independent acquisition (DIA) where there is no real-time selection of precursor ions 
based upon their abundance [54]. In DIA method, entire range of the precursor ions along 
with their MS/MS signals are acquired. The method allows the entire range of possible 
precursor ions mass to be analyzed that elutes from the nano-LC separation. Thus a 
mixture of several precursor ion fragments that co-elute and MS/MS spectra of the 
fragment ions from different peptides that co-dissociate irrespective of their abundance 
are acquired. This method offers a major advantage over the DDA method in identifying 
low abundance peptides that do not have significant precursor peak [55].  
 
 Bioinformatics. Bioinformatics tools provide protein scientists the ability to 
analyze thousands of MS scans that are generated from a mass spectrometer. The proteins 
are extracted from samples and enzymatically digested to generate peptides. These 
peptides can then be detected by mass spectrometer by tandem mass spectrometry and 
appropriate database search algorithms. In tandem mass spectrometry, the precursor ions 
generated from the source are further fragmented by colliding with an inert gas such as 
helium or nitrogen that produce product ions. The masses of the product ions then can be 
matched with in-silico fragment of parent ions and assigned various correlation and 
scoring factors based upon how close the obtained spectra match the theoretical spectra. 
The proteins are then identified by the software by the matched product ions which are 
selected based upon various scores and filters that come with the software along with the 
mass spectrometer that we use. The significance of the identified peptides is calculated by 
FDR scores. A large set of protein sequence database is available for proteome searches, 
among which the most commonly used are Swiss-prot (Uniprot), and NCBI. After the 
proteins are identified using the protein search databases and the tools, other 
bioinformatics tools such as PANTHER [56], ClueGO [57], IPA [58], and STRING [59] 
are needed for functional characterization of identified samples. These online tools 
provide the functional interpretation of the identified proteins, and thus biological 
significance can be predicted. 
 
 In the study reported here, three different multidimensional bioanalytical 
platforms were used to analyze the proteome in mitochondria. The main objective of the 
study was to evaluate the capabilities of these platforms in terms of the extent and the 






Figure 2-2. An example of tandem MS/MS in a data dependent acquisition 
setting. 
(A) Chromatogram of LC, (B) MS-Spectrum of analytes eluting at the LC retention time 
around 83.99 min, (C) MS/MS measurement of precursor ion with m/z 840. In data 
dependent acquisition the mass spectrometer first measures full MS scan is followed by a 
specific number of MS/MS scans. The above example shows Peptides dissociate in a 
particular fashion, and MS/MS spectrum of a peptide ion with m/z 840 shows a series of 




separation methods—PLRP (separation at the peptide level), in-gel IEF (separation at the 
protein level) and SDS-PAGE (separation at the protein level)—in combination with 
down-stream RP LC-MS/MS. Our investigation showed the superior performance of the 
SDS-PAGE-based platform. Survey of the mitochondrial proteome with this platform 
provided access to the highest number of mitochondrial proteins over a wide range of 
abundance levels. The mitochondria proteome profile that was obtained encompasses 
proteins with diverse functional characteristics. Thus, among the configurations 
evaluated, the SDS-PAGE-based platform was identified as the best choice as a 




Materials and Methods 
 
 
Protein Extraction  
 
 The protein samples for the study were obtained from 8 week old Sprague-
Dawley rats (n=6) which were approved by our Institutional Animal Care and Use 
Committee. The subsarcolemmal population of mitochondria was isolated by 
homogenization of freshly collected heart tissue samples followed by differential 
centrifugation. Interfibrillar mitochondria (IFM) was discarded after 1500xg, and the 
subsarcolemmal (SSM) mitochondria were collected after 10000xg centrifugation. To 
confirm the purity of isolated mitochondria, the mitochondrial preparation was stained 
with Mito Tracker Red which is a mitochondria-specific dye and analyzed by flow 
cytometry, as previously described [60]. 
 
 The individual (n=6) mitochondrial preparation were pooled. The protein mixture 
was then mixed with buffer containing 400mM of ABC (ammonium bicarbonate), 8M 
urea and 1% RapiGest and sonicated with sonicator probe four times for 30 seconds 
every 15 min intervals to extract proteins. The total protein concentration of the extracted 
proteins was quantified with the 2D-Quant protein assay kit (GE Healthcare, Piscataway, 
NJ, USA). The protein extract was divided into three equal portions and stored at -80 C 
until further processing. For each bioanalytical platform 400μg of protein was used, and 





 For isoelectric focusing the mitochondrial proteins were first dissolved in an IEF 
rehydration buffer consisting of urea (7 M), thio urea (2 M), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) detergent (2% w/v), 
immobilized pH gradient (IPG) buffer (carrier ampholyte mixture; 2% v/v) and DTT 
(0.3% w/v). The IPG strips used for protein separation were 18 cm long and had 
nonlinear 3-10 pH gradient. 130 μg of protein sample per strip was applied via passive 
IPG strip rehydration. Following parameters were used for focusing the protein samples: 
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0-100 V gradient for 1 min; 100 V fixed for 120 minutes; 100-500 V gradient over 1 min; 
500-3000 V gradient over 90 min and 3500 V constant for 8 hours. After the protein 
separation, the IEF strip was fixed with trichloroacetic acid (20% w/v) and with 
methanol: water: acetic acid (50:40:10 v: v: v). The strip was then divided into 15 





 Criterion XT 4%- 12% Bis-Tris gels (13.3 x 8.7 cm) from Bio-Rad was used for 
the SDS-PAGE separation. As mentioned earlier, 130 μg of protein was used in each 
replicate (n=3, technical replicate). 130 ug of protein sample was separated on 3 lanes 
(approximately 40ug per lane) at 200 V for 60 minutes. The separated lanes were stained 
with Coomassie Blue stain and then divided into 15 sections of equal size. The 8 cm gel 
was equally divided into 15 bands horizontally and cut into pieces manually and stored at 
-20 ˚C after image acquisition. 
 
 
In-gel Protein Digestion 
 
 Each section of the SDS PAGE was in-gel digested using the following protocol. 
The gel pieces were destained three times in 700uL of water/methanol solution (50:50, 
v/v) with 25mM ammonium bicarbonate buffer (ABC) (pH 8.0), changing the solution 
every 10 min. The gel pieces were then washed with 1 mL of an acetic solution (acetic 
acid/methanol/water, 10:40:50, v/v/v) for 3 h, changing the solution every 1 h. Then the 
gels were soaked in water for 20 minutes followed by 200nM ABC for next 20 minutes. 
The protein in IEF trip and processes SDS PAGE gel pieces were then reduced by 50mM 
DTT (in ABC) and alkylated with 110mM Idoacetamide and dried in a SpeedVac for 30 
min. after dehydration with ACN. Then 150ml of Trypsin, 1.09 ug/uL of sequence grade 
modified trypsin (Promega) was added to each gel pieces and were incubated overnight at 
37 ˚C. The tryptic digest was extracted by using 90% ACN, 0.1% TFA for 60 min with 
vortex, twice and dried with speed Vac. The extracted peptides were then cleaned with 
ZipTip C18 (Millipore) with 4ul of acetonitrile-water (v/v, 0.1% TFA) and diluted with 
6uL of 0.1% formic acid.  
 
 
In-solution Protein Digestion 
 
 For in-solution digestion, 400 μg of mitochondrial protein was digested and 
divided into three equal parts for PLRP separations. Each aliquot was then digested with 
trypsin (Promega, Madison, WI, USA) that was dissolved in 50nM ABC buffer at the 
ratio of 1:50, for 18 hours at 37 ˚C. The digest was then first acidified with trifluoroacetic 
acid (TFA), then peptide desalting was done by solid-phase extraction using a home-
made spin mini column that was filled with approx. 200mg of Vydac c18 packing 
material (Sigma Aldrich, St. Louis, MO, USA). The peptides were eluted with 400ul of 
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acetonitrile-water, 70:30 (v/v, 0.1% TFA) after washing three times with 500ul of water 
(0.1% TFA). The samples were stored at -80 ˚C until further use. 
 
 
High-pH Reversed-Phase Chromatography (PLRP)  
 
 The peptide solution eluted from in-solution protein digestion was reduced to 
approximately 10ul which was then mixed with 10ul of PLRP buffer A. Buffer A mobile 
phase is a mixture of water: ammonium hydroxide (30%); (99.8:0.2, v:v), pH 10). The 
peptide and buffer mixture was then injected into the polymer-based reverse phase 
column (PLRP-S, 5μm, 100A, 150x 2.1mm) from Agilent Technologies (Santa Clara, 
CA, USA). Elution of peptide was done with a linear gradient of buffer B, which consists 
of acetonitrile: water: ammonium hydroxide (30%); (80:19.8:0.2, v/v/v), pH 10, from 0-
90% for 95 minutes, which was followed by 5 min isocratic elution, 5 minutes re-
equilibration (90%-0% B) and 10 min isocratic. Peptides fractions, 15 fractions per 
samples, were collected using HPLC fraction collector (Spectra/Chrom, Model CF-1, 
Spectrum Chromatography, Houston, TX, USA). The peptide fractions were dried in a 
vacuum centrifuge, re-suspended in 10ul water with 0.1% TFA and stored at -80 ˚C until 





 After the first dimensional separation of the peptides, the second dimensional 
separation was done by home-packed Magic C18 (5 m, 200 A, Michrom Bioresources, 
Auburn, CA, USA) capillary column (100 mm × 75 μm I.D.) (New objective, Woburn, 
MA, USA). Four microliters of peptide digest were injected manually into nano injector 
(Idex, Oak Harbor, WA, USA). A flow rate of 300 nL/minute was used to elute the 
peptides with linear gradient for 95 min from solvent A ((water: acetic acid: formic acid), 
(97.9:2:0.1), v/v/v) to solvent B (water: acetic acid: formic acid), (9.9:90:0.1, v/v/v). LTQ 
ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) was used for 
mass analysis in a data-dependent scan mode with MS scan of 400-200m/z. The 7 most 






 The raw data from the mass spectrometer was analyzed by Proteome Discoverer 
software version 1.4 (Thermo Fischer Scientific, Waltham, MA, USA). Sequest HT for 
rat database (swiss-prot; number of protein sequences 28,885; version 06/27/2013) that 
was digested in-silico with trypsin was used. The criteria to select the protein in proteome 
discoverer are as follows; only fully tryptic peptide was considered, precursor error 
tolerance was selected to 1.5 Da, product ion tolerance was 0.8 Da, peptide modification 
selected for dynamic modifications were methionine oxidation, lysine acetylation and 
that static modification was carbamidomethylation of cysteine. Percolator was used to 
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calculate the false discovery rate for matched peptides which considered peptides with 
PEP score of 0.01 or lower to be a positive match. 
 
 Data analysis was done by GraphPad Prism (v5.0.4; La Jolla, CA, USA). To 
calculate the GRAVY peptide and protein score the parameters described by Kyte and 
Doolittle were used which calculated the scores based upon hydrophobicity of amino 
acid. The PANTHER protein classification system was used to analyze the Gene 
Ontology (GO) annotations which identified the functional annotations. TargetP server 
was used to predict the sub-cellular location of the identified proteins. Cytoscape (v3.0.2) 
plug-in ClueGo was used for the biological interpretation of identified proteins. Swiss-
Prot and primary literature were used to obtain information on protein functions. 
 
 
Results and Discussion 
 
 In this study, we evaluated three multidimensional bioanalytical platforms for 
protein profiling. The overall experimental scheme is presented in Figure 2-3. Both gel-
based and gel-free prefractionation methods were included in our study. For the gel-based 
method, we used IEF and SDS-PAGE analysis that separated the intact proteins in the 
first dimension. After the proteins were separated, the gels were divided equally into 15 
fractions and processed for in-gel digestion with trypsin. The tryptic peptide mixtures 
were separated in the second dimension with reverse phase LC interfaced with MS/MS. 
The data from mass spectrometric analysis were analyzed by proteome discoverer, and 
the list of identified proteins was generated for each gel section. The list of proteins 
identified from each section was finally combined to generate a final list of proteins for 
each bioanalytical platform. For the gel-free pre-fractionation, the protein mixture was 
first digested with trypsin and peptide level separation was performed by reverse phase 
LC at high pH (PLRP). In this analytical platform also 15 peptide fractions were 
collected which were then separated in the second dimension by reverse phase LC and 
analyzed by mass spectrometer. As the gel-based methods, the proteins lists identified in 
each of the 15 fractions were combined, and a list of proteins for this analytical platform 
was created. Three technical replicates for each platform were performed. We also 
analyzed unfractionated samples by mass spectrometric analysis and compared it to the 
fractionated samples. Fractionation helped in the identification of a higher number of 
proteins and gave better proteome coverage (Table 2-1). Also, various proteins related to 
important functional modules such as TIM/TOM protein import, and fusion/fission 
proteins could not be identified in unfractionated samples. 
 
 
Summary of Protein Identification Results 
 
 As shown in Table 2-2, for each of the bioanalytical platform, 15 peptide 
mixtures were analyzed by LC-MS/MS in three technical replicates. The total number of 
LC-MS/MS analyses performed in this this bioanalytical comparison study was 135. 





Figure 2-3. Experimental scheme for the comparative evaluation of three 
bioanalytical platforms for mitochondrial proteome profiling. 
(A) or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (B); or 
by PLRP (polymeric reversed-phase liquid chromatography at high pH) at the peptide 
level following proteolytic digestion (C). Fifteen gel sections (A, B) or 15 liquid fractions 
(C) were produced, and the peptide mixtures were analyzed by liquid chromatography-
mass spectrometry/mass spectrometry (LC-MS/MS). The LC-MS/MS data were used to 
identify the proteins sampled with each platform. Three technical replicates were 




Table 2-1. Total proteins identified in fractionated vs. unfractionated samples. 
 
Sample Processing Number of Proteins Identified 
Unfractionated 213 










Technical Replicate   
Total Run Repeat-1 Repeat-2 Repeat-3  
SDS-PAGE 15 15 15  45 
PLRP 15 15 15  45 




discovery rates (FDR). The peptides were deemed positive if the PEP scores were <0.01 
for fully tryptic peptides. A total number of 1043 unique proteins were identified by all 
the platforms combined. A full list of proteins identified with each platform is provided 
in Supplementary Table Listing Number of Proteins Identified. 
 
 There was a pronounced difference in the performance of the three analytical 
platforms in mapping the total proteome. Table 2-3 summarizes the protein identification 
results. SDS-PAGE based analytical platform identified 890 proteins, IEF based 
analytical platform identified 600 proteins and PLRP identified 450 proteins in total. 
Therefore, SDS-PAGE based platform identified the highest number of proteins among 
the three platforms.  In addition, the SDS-PAGE based platform also identified the 
highest number of peptides giving the highest protein coverage. The total peptide counts 
for IEF based platform was 50% less than that of SDS-PAGE based platform. Also, there 
was only 32.7% overlap of proteome coverage between the three platforms. The 
distribution of unique proteins identified by each platform and the protein overlaps 
among all the three individual platforms are shown in Figure 2-4. 
 
 
Intrinsic Chemical Properties of Identified Proteins 
 
 Three different intrinsic chemical properties of the proteins identified with each 
platform viz. GRAVY (grand average of hydropathy) Score; Molecular weight (Mw); 
and isoelectric point (pI) were assessed. The identified proteins by these three platforms 
showed similar trends based on these intrinsic parameters (Figure 2-5). The only major 
difference seen among these platforms was in the high molecular weight section, the 
SDS-PAGE based platform identified a significantly greater number of high molecular 
weight proteins (p < 0.001) (Figure 2-5B). Also, regardless of the bioanalytical 






 Performance of the three bioanalytical platforms used in this study in terms of the 
dynamic range of protein coverage was assessed. For this purpose, the relative protein 
abundance was calculated using normalized spectral abundance factors (NSAF).     
Figure 2-6 shows that all the three platforms were able to sample proteins over a wide 
range of abundance level. In this scenario too the SDS-PAGE based platform was found 
to be superior as it was able to provide the most in-depth coverage of mitochondrial 
proteins with the dynamic range spanning five orders of magnitude, i.e., from 10-1 to 10-6. 
 
 
Categorization of the Identified Proteins 
 
 The proteins in the panels identified by each bioanalytical platforms were 
analyzed for their cellular localizations by ClueGO [61] and, biological processes by 
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Table 2-3. Summary of the performances of three gel-based and gel-free 
bioanalytical platforms for mitochondrial proteome mapping. 
 
Performance Characteristic SDS-PAGE IEF PLRP 
Number of proteins-----replicate 1 708 520 315 
Number of proteins-----replicate 2 726 468 330 
Number of proteins-----replicate 3 696 476 361 
Average ± SD 710 ± 15 488 ± 28 335 ± 23 
C.V. 2.1% 5.7% 7.0% 
Total number of proteins (all runs) 890 600 450 
Total number of peptides (all runs) 6023 3110 1671 
Proteome coverage overlap  64% 63% 53% 
Total number of proteins (all platform) 1043 - - 









Figure 2-4. Venn diagrams showing the distribution of unique proteins identified 
by each platform. 
(A) Top portion of the figure shows the overlap for each platform among the three 







Figure 2-5. Distribution of intrinsic properties of the mitochondrial proteins 
identified by each platform. 












PANTHER [62]. The top cluster that was common to all the three bioanalytical platforms 
was metabolic processes (GO:008152). Around 41% to 49% of the total protein identified 
fall in this group, which is one of the main functions of mitochondria (Figure 2-7). 
Similarly, the proteome panel obtained from our study was also analyzed for the presence 
of N-terminal mitochondrial targeting sequences (MTS) by using TargetP [63]. All the 
platforms showed similar results, i.e., among all the proteins identified by each platform 
around 50% of the proteins identified contained MTS (Figure 2-8). MTS helps proteins 
migration towards mitochondria after their syntheses. However, there are other 




Selected Functional Characteristic of Mitochondrial Proteome Panel 
 
 The catalog of protein panel from this study was from mitochondrial proteins. So, 
we selected five major functional modules of mitochondria and analyzed if the identified 
proteins belong to these modules. It was found that most of the identified mitochondrial 
proteins belonged to the electron transport chain (ETC)/oxidative phosphorylation 
(OXPHOS) module as proteins are one of the major clusters of the mitochondrial system. 
A total of 89 OXPHOS proteins were identified and are listed in Table 2-4. The oxidative 
phosphorylation metabolic pathway consists of five ETC/OXPHOS protein complexes, 
and the list of proteins, identified in our study included protein subunits from all five 
ETC/OXPHOS complexes. The proteins that belong to the component of mitochondrial 
ribosome were the second major functional modules identified by the proteome panel in 
which 39 members of the mitochondrial ribosomes were identified. Similarly, 17 
members of the TIM/TOM protein machinery were identified in our study. These 
proteins play an important role in protein translocation into the mitochondria. The other 
important functional clusters are proteins that play a crucial role in mitochondrial fusion 
and fission. Dynamin-like 120 kDa protein-OPA1, mitofusin-1 that belongs to 
mitochondria fission and fusion [65], along with other three proteins, were also 
identified. In addition, sirtuin 3 and sirtuin 5 that belong to a protein deacetylase family 





 Over the past 15 years, mass spectrometry-based workflows (i.e., workflows that 
by-pass traditional 2D-PAGE) have been increasingly used for protein identification and 
quantification in proteomics. In order to effectively probe a complex proteome, upstream 
pre-fractionation may be considered. There are a number of different pre-fractionation 
strategies available. In our study, we compared three multidimensional bioanalytical 
platforms that incorporate different means of protein/peptide fractionation. We selected 
IEF, SDS-PAGE, and PLRP separations. All three methods were easy to set up in our 
laboratory because no specialized equipment was required to perform these separations, 






Figure 2-7. Gene ontology categorization of the identified proteins according to 






Figure 2-8. Distribution of proteins according to the presence of N-terminal 




Table 2-4. Representative proteins from selected functional classes. 
 
Accession Description 
P15999 ATP synthase subunit alpha, mitochondrial 
G3V6D3 ATP synthase subunit beta 
Q66HF1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
Q920L2 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 
P32551 Cytochrome b-c1 complex subunit 2, mitochondrial 
P19511 ATP synthase subunit b, mitochondrial 
Q68FY0 Cytochrome b-c1 complex subunit 1, mitochondrial  
P35435 ATP synthase subunit gamma, mitochondrial  
P20788 Cytochrome b-c1 complex subunit Rieske, mitochondrial  
Q5BK63 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial  
Q06647 ATP synthase subunit O, mitochondrial  
Q5XIH3 NADH dehydrogenase (Ubiquinone) flavoprotein 1  
D3ZG43 NADH dehydrogenase (Ubiquinone) Fe-S protein 3 (Predicted), isoform CRA_c  
P31399 ATP synthase subunit d, mitochondrial  
P00406 Cytochrome c oxidase subunit 2  
Q2TA68 Dynamin-like 120 kDa protein, mitochondrial  
Q561S0 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial  
P10888 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  
P11240 Cytochrome c oxidase subunit 5A, mitochondrial  
Q641Y2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial  
D4A0T0 Protein Ndufb10  
Q6PDU7 ATP synthase subunit g, mitochondrial  
P21913 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  
D3ZE15 Protein LOC100911483  
D3ZLT1 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 7 (Predicted)  
Q63362 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5  
B0BNE6 NADH dehydrogenase (Ubiquinone) Fe-S protein 8 (Predicted), isoform CRA_a  
Q5XIF3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial  
F1LXA0 NADH dehydrogenase (Ubiquinone) 1 alpha subcomplex, 12 (Predicted), isoform CRA_b 
Q5RJN0 NADH dehydrogenase (Ubiquinone) Fe-S protein 7  
P19234 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  
Q8SEZ0 NADH-ubiquinone oxidoreductase chain 5  
D3ZD09 Cytochrome c oxidase subunit 6B1  
P12075 Cytochrome c oxidase subunit 5B, mitochondrial  
Q80W89 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11  
D4A565 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 5 (Predicted), isoform CRA_b  
D4A7L4 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 11 (Predicted)  
B2RYS2 Cytochrome b-c1 complex subunit 7  
B2RYS8 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex 8  
P29419 ATP synthase subunit e, mitochondrial  
B5DEL8 NADH dehydrogenase (Ubiquinone) Fe-S protein 5  
B2RYW3 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 9  
B2RZD6 Ndufa4 protein  
H9KVF8 NADH-ubiquinone oxidoreductase chain 1 (Fragment)  
Q5PQZ9 NADH dehydrogenase [ubiquinone] 1 subunit C2  
Q7TP78 Aa2-258  
P05508 NADH-ubiquinone oxidoreductase chain 4  
G3V7Y3 ATP synthase subunit delta, mitochondrial  
P10817 Cytochrome c oxidase subunit 6A2, mitochondrial (Fragment)  
P11951 Cytochrome c oxidase subunit 6C-2  
D3ZAF6 ATP synthase subunit f, mitochondrial  
D4A3V2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6  
D3ZZ21 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 6 (Predicted)  
Q5M9I5 Cytochrome b-c1 complex subunit 6, mitochondrial  
P35171 Cytochrome c oxidase subunit 7A2, mitochondrial  
A9UMV9 Ndufa7 protein  
Q7TQ16 Cytochrome b-c1 complex subunit 8  
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Table 2-4 (Continued.) 
 
Accession Description 
D3ZS58 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2  
P11608 ATP synthase protein 8  
H9KVF5 NADH-ubiquinone oxidoreductase chain 3 (Fragment)  
G3V640 Mitochondrial import inner membrane translocase subunit TIM44  
Q5U2X7 Mitochondrial import inner membrane translocase subunit Tim21  
D3ZJX5 Protein Timm50  
P21571 ATP synthase-coupling factor 6, mitochondrial  
D3ZYX8 Cytochrome c oxidase subunit VIIa polypeptide 2 like (Predicted), isoform CRA_e  
Q75Q41 Mitochondrial import receptor subunit TOM22 homolog  
P05503 Cytochrome c oxidase subunit 1  
Q6PCU8 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial  
P11662 NADH-ubiquinone oxidoreductase chain 2  
P80432 Cytochrome c oxidase subunit 7C, mitochondrial  
P05505 Cytochrome c oxidase subunit 3 
O08776-4 Isoform 4 of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3  
P52504 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial  
D3ZN43 NADH dehydrogenase (ubiquinone) complex I, assembly factor 6  
B2RZ31 Protein Sirt3  
P84817-3 Isoform 3 of Mitochondrial fission 1 protein  
P62076 Mitochondrial import inner membrane translocase subunit Tim13  
Q9WV97 Mitochondrial import inner membrane translocase subunit Tim9  
Q62760 Mitochondrial import receptor subunit TOM20 homolog  
F1M8L6 Protein Ndufa3  
O35092 Mitochondrial import inner membrane translocase subunit Tim17-A  
G3V9S0 Cytochrome b5 reductase 1 
Q06645 ATP synthase lipid-binding protein, mitochondrial  
Q9NQR8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4  
R9PXR4 Mitochondrial import receptor subunit TOM70  
G3V644 NADH dehydrogenase (Ubiquinone) flavoprotein 3-like, isoform CRA_a  
Q6PCT8 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial  
D3ZTW7 ATP synthase mitochondrial F1 complex assembly factor 2 (Predicted), isoform CRA_c 
O35093 Mitochondrial import inner membrane translocase subunit Tim23  
F1LWG4 NADH dehydrogenase (Ubiquinone) 1 alpha subcomplex, assembly factor 1 (Predicted), isoform 
CRA_a 
P62078 Mitochondrial import inner membrane translocase subunit Tim8 B  
Q9WVA1 Mitochondrial import inner membrane translocase subunit Tim8 A  
Q68FX9 NAD-dependent protein deacylase sirtuin-5, mitochondrial  
Q8R4Z9 Mitofusin-1 
Q5XIM4 ATP synthase subunit s, mitochondrial  
A9UMV7 Protein Uqcr11 
B2RYU0 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 2 (Predicted), isoform CRA_b  
D3ZZV1 Mitochondrial import inner membrane translocase subunit TIM16  
Q7H113 NADH-ubiquinone oxidoreductase chain 4  
P29418 ATP synthase subunit epsilon, mitochondrial  
D3ZY50 ATP synthase mitochondrial F1 complex assembly factor 1 (Predicted), isoform CRA_a  
P05504 ATP synthase subunit a  
Q5I0I4 ATP synthase subunit s-like protein  
Q5RJQ7 Succinate dehydrogenase assembly factor 2, mitochondrial  
G3V8F5 Mitochondrial import receptor subunit TOM40 homolog  
P10818 Cytochrome c oxidase subunit 6A1, mitochondrial  
G3V9S6 Protein Ndufa1 
Q5BJN5 Mitochondrial intermembrane space import and assembly protein 40  
Q9JKW1 Mitochondrial import inner membrane translocase subunit Tim22  
A4F267 Mitochondrial import receptor subunit TOM40B  
Q5XI79 NADH dehydrogenase [ubiquinone] complex I, assembly factor 7  
Q4KM98 Mitochondrial fission factor 
Q5XII9 Mitochondrial fission regulator 1-like  




Note: Color codes: ETC/OXPHOS – ORANGE; FUSION/FISSION – GREEN; TIM/TOM PROTEIN IMPORT 
– BLUE; MITOCHONDRIAL RISOBOME - PURPLE; OTHERS-BLACK 
  
Table 2-4. (Continued.) 
  
Accession Description 
B2RYU0 NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 2 (Predicted), isoform CRA_b  
D3ZZV1 Mitochondrial import inner membrane translocase subunit TIM16  
Q7H113 NADH-ubiquinone oxidoreductase chain 4  
P29418 ATP synthase subunit epsilon, mitochondrial  
D3ZY50 ATP synthase mitochondrial F1 complex assembly factor 1 (Predicted), isoform CRA_a  
P05504 ATP synthase subunit a  
Q5I0I4 ATP synthase subunit s-like protein  
Q5RJQ7 Succinate dehydrogenase assembly factor 2, mitochondrial  
G3V8F5 Mitochondrial import receptor subunit TOM40 homolog  
P10818 Cytochrome c oxidase subunit 6A1, mitochondrial  
G3V9S6 Protein Ndufa1 
Q5BJN5 Mitochondrial intermembrane space import and assembly protein 40  
Q9JKW1 Mitochondrial import inner membrane translocase subunit Tim22  
A4F267 Mitochondrial import receptor subunit TOM40B  
Q5XI79 NADH dehydrogenase [ubiquinone] complex I, assembly factor 7  
Q4KM98 Mitochondrial fission factor 
Q5XII9 Mitochondrial fission regulator 1-like  
B2GV62 Mitochondrial ribosomal protein L20  
Q63750 39S ribosomal protein L23, mitochondrial  
D3ZX69 39S ribosomal protein L10, mitochondrial  
P0C2C0 39S ribosomal protein L22, mitochondrial  
D4ABM5 Mitochondrial ribosomal protein S34 (Predicted), isoform CRA_a  
F1LMZ4 Ribosome-releasing factor 2, mitochondrial  
Q9EPJ3 28S ribosomal protein S26, mitochondrial  
Q6PDW6 39S ribosomal protein L17, mitochondrial  
D4A131 Mitochondrial ribosomal protein L4 (Predicted), isoform CRA_b 
Q7TQ82 28S ribosomal protein S10, mitochondrial  
B2RZ57 Mitochondrial ribosomal protein L18  
Q5I0K8 28S ribosomal protein S7, mitochondrial  
D3ZMR9 Mitochondrial ribosomal protein L21 (Predicted), isoform CRA_a  
D3ZYT2 Mitochondrial ribosomal protein S5 (Predicted)  
D4A4B1 Mitochondrial ribosomal protein L15 (Predicted), isoform CRA_c  
Q4G067 Mitochondrial ribosomal protein L44  
Q6AXT0 39S ribosomal protein L37, mitochondrial  
B0BN68 Mitochondrial ribosomal protein S9  
Q0ZFS4 Mitochondrial ribosomal protein S33 (Predicted), isoform CRA_a  
Q5XFW4 Mitochondrial ribosomal protein L13  
Q5XIE3 39S ribosomal protein L11, mitochondrial  
D3ZIN7 Mitochondrial ribosomal protein S23 (Predicted), isoform CRA_b  
Q5RK00 39S ribosomal protein L46, mitochondrial  
F6Q5K7 Mitochondrial ribosomal protein S18B, isoform CRA_a  
P18665 39S ribosomal protein L3, mitochondrial  
Q5M818 39S ribosomal protein L16, mitochondrial  
B0BN56 28S ribosomal protein S31, mitochondrial  
Q5PQN9 39S ribosomal protein L38, mitochondrial  
B2RYT0 Mitochondrial ribosomal protein S21 (Predicted), isoform CRA_a  
B2RYW4 Mitochondrial ribosomal protein L53  
P0C2C1 39S ribosomal protein L30, mitochondrial  
D3ZYL4 Mitochondrial ribosomal protein L50 (Predicted)  
D4A3E8 Mitochondrial ribosomal protein S27 (Predicted), isoform CRA_b  
D4A4V1 Mitochondrial ribosomal protein S18C (Predicted), isoform CRA_a  
Q641X9 39S ribosomal protein L9, mitochondrial  
D3ZYT2 Mitochondrial ribosomal protein S5 (Predicted)  
D4A4B1 Mitochondrial ribosomal protein L15 (Predicted), isoform CRA_c  
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fractions generated in each platform was chosen to be 15, which we considered to be a 
good balance between the time required to complete analyses of the multiple fractions 
generated from each proteome sample vs the enhancement of proteome coverage 
afforded by incorporation of these multidimensional separations. As expected, compared 
to proteome coverage attained with no up-stream fractionation, inclusion of 
multidimensional separation greatly increased the number of proteins being sampled.  
Our results demonstrate that SDS-PAGE based platform can provide the best proteome 
coverage when compared to the other platforms. The better performance of SDS-PAGE 
may be due to better protein solubility and protein denaturation due to the use of SDS. 
The IEF based platform also uses chaotropic agents that denatures the proteins. However, 
due to the strong denaturing property of SDS and smaller pore size of SDS-PAGE as 
compared to IEF gel strips, the former outperformed IEF based platform. The higher pore 
size of IEF increases the chance of loss of the protein from gel plug during sample 
processing which involves washing steps. However, when the gel-free method PLRP is 
compared with gel-based methods, both the gel-based methods outperformed the gel-free 
method. The better performance of gel-based methods attributes to the protein 
denaturation by chaotropic agents in the gel-based method and, more efficient sample 
proteolysis and incomplete samples recovery from PLRP column in the gel-free method.  
 
 Considerations of throughput are important when evaluating the suitability of a 
chosen platform for comparative proteome profiling, in which the analytical objectives 
include global-scale protein identification as well as relative quantification of protein 
expression levels in different samples, e.g. diseased vs. control specimens, cells treated 
with an exogenous agent postulated to induce proteome alterations, etc. Comparative 
proteomics studies necessitate examination of multiple replicates per sample group to 
obtain statistically significant data, and hence a large number of samples need to be 
analyzed by the chosen workflow. With the SDS-PAGE based platform set up as 
described in this Chapter, 15 LC-MS/MS analyses per each sample were performed to 
probe close to 900 proteins in this high proteome-complexity sample. It would be 
possible to apply this platform to comparative proteome profiling; however, from the 
analytical standpoint such study would represent a major time- and resource-demanding 
undertaking. A possible compromise between throughput vs. proteome coverage 
demands is to decrease the number of fractions (SDS-PAGE gel sections) processed in 
the workflow. Several studies have shown that using short SDS-PAGE, i.e., 5-10 minutes 
or 1cm of separation instead of full separation (15 cm), in which 4 gel sections are 
procured, provides a reasonable proteome coverage and requires fewer LC-MS/MS 
analyses [67-69]. However, since the completion in 2014 of the study presented in this 
chapter, our laboratory acquired a new state-of-the-art LC-MS/MS system (Waters 
Acquity M-class UPLC coupled to Synapt G2 Si) that enabled a major transformation in 
the down-stream portion of our proteomics workflows. This LC-MS/MS instrument 
combines superior LC separation, additional separation dimension via ion mobility, high 
resolution/high mass accuracy mass spectrometry and DIA capabilities. Coverage of a 
complex proteome (i.e., the number of proteins identified and quantified) achievable with 
this LC-MS/MS system without additional up-stream fractionation is 3,000-3,500 
proteins. For this reason, in the later portion of my research focused on qualitative and 
quantitative proteomics of ARPE-19 cells (Chapter 5), I applied the workflow that uses 
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CHAPTER 3.    SCAVENGER RECEPTOR-MEDIATED UPTAKE AND 





 The human eye is an important and delicate sensory organ [72]. When light rays 
pass through the cornea, the lens helps to focus the light rays on the retina. The light is 
then converted into electrochemical impulses by the cells in the retina. The impulses are 
transferred to the brain via optic nerve which helps us to view any object [73]. Retina is 
the light sensitive tissue lining the back of the eye. In the center of the retina lies the 
macula. It is characterized by a central thinner dip, the fovea, which is the only area 
where sharp vision is possible (Figure 3-1A). It is the part of the eye that is responsible 
for central sharp visual acuity. Any process that damages the integrity of the macula, 
particularly the fovea, compromises central vision and visual acuity. Retina consists of 
several layers as follows: i) Inner limiting membrane, ii) Nerve fiber, iii) Ganglion cell 
layer, iv) Inner plexiform layer, v) Inner nuclear layer, vi) Outer plexiform layer, vii) 
Outer nuclear layer, viii) External limiting membrane, ix) Layer of rods and cones and x) 
Retinal pigment epithelium [74]. Among these layers, only photoreceptor cells rods and 
cons are directly sensitive to light [75]. These photoreceptor cells are supported by the 
retinal pigment epithelium (RPE). The RPE is a hexagonal, pigmented monolayer which 
is tightly packed with tight junction and adherens junctions proteins and forms the outer 
blood-retinal barrier (BRB). RPE layer of the eye is the part of the human eye that is most 
affected due to Age-related Macular Degeneration (AMD). The RPE has an intimate 
connection with the photoreceptors on its apical side for numerous reasons. First, the 
RPE phagocytoses 10% of the photoreceptor outer segments every day to recycle the 
retinal chromophore and remove damages caused by photo-oxidation of lipids and 
proteins to ensure proper photoreceptor function. Second, the RPE supplies oxygen and 
metabolites (including the retinal chromophore) to the rod and cone photoreceptors and 
forms the blood-retinal barrier that isolates the retina from the systemic circulation [76]. 
The basolateral side of RPE lie the Bruch’s membrane and choroid capillaries which 
form an important part of blood retinal barrier (BRB). It plays an important role in the 
uptake of ions and nutrients, removing the metabolic waste from subretinal space. It also 
produces immunosuppressive factors that preserve the immune privilege of the eye [77]. 
 
 AMD is the leading cause of visual impairment in elderly populations. The 
progression of AMD results in irreversible damage to the macula of the eye [78]. AMD is 
the third largest cause of visual impairment worldwide. In the United States alone, AMD 
affects roughly 10 million individuals and over 2 million of these suffer from late-stage 
AMD which severely affects the quality of life and increases the public health burden. 
There is no effective treatment available for most AMD cases, and for those able to be 
treated, the treatment is far from 100% effective [79]. 
 
 The early stages of AMD are termed age-related maculopathy or ARM. At the 






Figure 3-1. Stages of AMD. 
(A) Diagram of the eye, shows the macula which is the central part of retina affected in 
AMD (B) Early drusen, the early stage which is called age related maculopathy.(C) 
Geographic Atrophy also called dry AMD which is characterized by the presence of 
drusen, (D) Choroidal Neovascularization also called wet AMD which is characterized by 
presence of blood vessel in the retina. 
 
Image A reprinted with permission from an artwork by Holly Fischer obtained from 
https://commons.wikimedia.org/wiki/File:Three_Internal_chambers_of_the_Eye.png. 





changes and deposits known as drusen (discussed further below) are already present at 
this stage (Figure 3-1B). At this stage, every form of the ARM is considered dry. As the 
tissue suffering increases and progresses in extent and severity over time, the advanced 
stages of AMD develop, leading to actual vision loss and other symptoms experienced by 
the affected patients. Advanced AMD is mainly classified into two broad forms: 
geographic atrophy and wet AMD.  Geographic atrophy is the advanced stage of dry 
AMD, characterized by progressive RPE atrophy and loss, which ultimately leads to 
functional compromise, the death of the overlying photoreceptors and vision loss. 
Extensive progression of the processes is sketched in Figure 3-1B. Drusen are often 
associated with geographic atrophy, and usually, their presence precedes RPE and 
photoreceptor loss. Geographic atrophy accounts for 80 to 90% of the advanced AMD 
cases [80]. Wet AMD, referred to also as neovascular (nv)AMD, accounts for the 
remaining 10-20% of advanced AMD and is characterized by the development of 
choroidal neovascularization (CNV), i.e., the growth of abnormal blood vessels from the 
choroid that penetrates the BM RPE and the macula. The newly formed blood vessels 
leak blood into the retina causing distortion of vision and eventually central vision loss 
(Figure 3-1C). Drugs that lead to CNV regression after it develops have been discovered 
and have become a mainstay of nvAMD treatment. However, ways to prevent the 
development of CNV as well as dry AMD have yet to be identified. 
 
 
Pathophysiology of AMD: Genetic and Environmental Factors 
 
 AMD is a multifactorial disease that involves contributions from both 
environmental and genetic factors. Age, gender, race, cigarette smoking, diet, and various 
other cardiovascular risk factors have been identified as potential agents in the 
progression of AMD by various studies [79, 81]. The environmental exposure comprises 
around 30-55% of the attributable risk for the AMD whereas genetic factor is described 
to attribute the remaining 45-70% [82]. The major environmental factors that pose a risk 
for the development of AMD include increasing age, smoking, and low intake of dietary 
antioxidants. Other risks include higher body mass index, serum cholesterol, cataract 
surgery, cardiovascular diseases, hypertension, nutrition, and ultraviolet light exposure. 
 
 Age remains the major risk factor for AMD while cigarette smoking is the most 
strongly correlated environmental factor for AMD. It has been shown that disease 
progression is strongly influenced by smoking and the risk for dry AMD is reduced by 
smoking cessation [83]. Omega-3 fatty acid (FA) intake was found to be associated with 
lower risk of AMD in a recent epidemiologic study, showing correlations between AMD 
and lipid intake [84]. 
 
 Occurrence of AMD also differs among race populations with the frequency of 
early signs of AMD at 4.2% in Hispanic populations, 5.4% in Caucasian populations and 
2.4% in African American populations [81]. Thus, the different ethnic groups have 
different susceptibilities to AMD. It had been known for decades that genetic factors 
played a role in AMD. For instance, twin and family-based studies revealed a much 
greater risk of developing AMD among twins and first-degree relatives [85]. However, it 
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was not until 2005 that the first direct link to a genetic factor was identified by Dr. 
Hageman's group . The group identified that mutations in the complement factor H 
(CFH) gene caused a form of glomerulonephritis also characterized by the presence of 
extensive drusen is risk factor associated with AMD [86]. Following this discovery, 
genetic association analyses of AMD identified a non-synonymous single nucleotide 
polymorphism (SNP) at codon 402 (Y402H) in CFH as a major genetic risk factor in the 
AMD [87, 88]. This new discovery paved the way towards a formal role for inflammation 
and immune response dysregulation in AMD pathogenesis.  Following this initial 
discovery, 20 chromosomal regions have been identified that contain genetic variants 




Oxidative Stress and AMD Pathology 
 
 The factors that contribute to the cause of AMD such as smoking, diet, sunlight 
exposure, and vitamin D levels all are known to exhort oxidative stress. The Age-Related 
Eye Disease Study (AREDS) was one of the first studies that highlighted the role of 
oxidative stress as a disease contributor to macular degeneration. The study conducted by 
the National Eye Institute (NEI) showed that the use of antioxidant agents such as 
vitamin C, vitamin E, beta-carotene, and zinc ameliorated AMD [89]. Moreover, the RPE 
layer in the human eye is located between the photoreceptor which is prone to light-
induced oxidative damage and the choroid that has a high supply of oxygen [90]. The 
phagocytosis process by RPE also generates a strong load of free radicals that make RPE 
more susceptible to oxidative stress. In normal condition, the RPE is capable of removing 
the free radicals with its own antioxidative mechanism. However, as we age the ability of 
RPE to compensate the oxidative damage reduces, which leads to series of events that 
contribute to macular degeneration in the elderly population. One of the reasons for the 
disruption in the phagocytosis of the POS by RPE is due to the accumulation of lipid and 
lipid peroxidation products. The presence of drusen deposits is known to increase the risk 
of progression of AMD. The human drusen accymulate in the extracellular sub-space and 
consist of lipids, proteins, cellular debris and oxidized lipids. The lipids in the RPE 
originate primarily from the photoreceptors that are phagocytosed, and these are 
accumulated with age in Bruch’s membrane known as basal linear deposits. The linear 
deposits are considered as a precursor of drusen formation [91, 92]. The 
immunohistochemistry of AMD specimen has shown the staining of oxidized lipids in the 
Bruch’s membrane and basal deposits [93].  
 
 Various mass spectrometry based proteomic studies have shown the presence of 
iron and myeloperoxidase which are highly potent factors that can trigger an oxidative 
process on proteins and lipids that are accumulated in Bruch’s membrane. The low-
density lipoprotein (LDL) present in a pro-oxidant tissue environment is then oxidized to 
form oxLDL in which both lipids and proteins become oxidatively modified [94]. The 
oxLDL is a mixture of a heterogeneous group of macromolecular complexes that consist 




Table 3-1. Genes identified to be associated with AMD. 
 
Biological Pathways Genes 
The complement pathway and immune response CFH, C2/CFB, CFI, C3 and C9 
  
Lipid Transport APOE,LIPC,CETP,BAIAP2L2 
  
Cell survival/DNA repair/Apoptosis/ Stress response  ARMS2,RAD51B, TNFRSF10A 
  
Angiogenesis VEGFA, TGFBR1, ADAMTS9 
  





(apoB). OxLDL bears lipid peroxidation-derived structural moieties called oxidation-
specific epitopes (OSEs) which enable recognition of oxLDL by cellular and soluble 
pattern recognition receptors (PRRs). The PRRs mediate clearance of oxLDL as part of a 
protective response by the innate immune system to maintain cellular homeostasis [95]. 
 
 AMD lesion formation has been hypothesized to be similar to the mechanism of 
formation of atherosclerosis lesions. Both diseases hold common underlying defect where 
there is deposition of lipids. Both the eye and the arteries are unable to remove the 
cholesterol deposits effectively. The “response to retention” hypothesis that is widely 
supported for atherosclerosis states that lipoprotein particles enter the intima of the 
arteries and bind to specific proteoglycans [96]. These retained lipoproteins are oxidized 
to oxLDL which is then internalized by macrophages via scavenger receptors mainly 
CD36 and SR class A (SR-A). This leads to the formation of foam cells that induce the 
cascade of molecular events that eventually lead to the formation of atherosclerosis 
plaques. Since various groups have already demonstrated the presence of cholesterol, 
lipids, and apo-lipoproteins in Bruch’s membrane, retention of these lipoproteins in the 
Bruch’s membrane and their oxidative modification is postulated to initiate the cascade of 
events that brings pathophysiological complications in the eye [97].  
 
 
Scavenger Receptors of OxLDL 
 
 Scavenger receptors are a group of receptors that are structurally diverse and can 
be membrane bound or soluble. These receptors are known to identify macromolecules, 
the modified low-density lipoprotein (either by acetylation and oxidation), and various 
pathogens, damage-associated molecular patterns (DAMPs) [98] and pathogen-associated 
molecular patterns (PAMPs)[99]. The role of scavenger receptors in the uptake of 
oxidized lipids and contribution to the formation of plaques in atherosclerosis lesions is 
well accepted [100]. There are various scavenger receptors, e.g., CD36, SRB1, and 
SRBII, present in the eye that are responsible for oxLDL uptake [101]. In the rest of the 
chapter, I would discuss the two scavenger receptors CD36 and CD5L/AIM that are the 
main focus of our study. 
 
 CD36 is 80kD, a transmembrane protein which is extensively glycosylated, found 
in a variety of epithelial and endothelial cells including platelets, immune cells, 
adipocyte, monocyte, retinal and mammary epithelial cells [102]. Structurally, CD36 has 
both the N and C-termini located in the cytoplasm and a larger extracellular loop with 
two transmembrane domains [103]. CD36 binds to many ligands long chain fatty acid, 
oxidized phospholipids, and has been implicated in diseases such as malaria, thrombosis, 
and atherosclerosis [104-106]. The extracellular domain at amino terminal is known to 
contain a binding pocket for oxidized lipids and fatty acids, phospholipids, erythrocytes 
infected with Plasmodium falciparum. The fatty acids bind at the lysine 164 in the fatty 
acid binding site, which overlaps with oxLDL binding site near the 155–183 sequence 
[107], initiating its uptake [108]. Various studies have shown that this binding can be 
blocked by the use of small molecule sulfo-N-succinimidyl oleate (SSO) which binds 
irreversibly to the lysine 164 in the CD36 binding pocket blocking the transport of 
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oxidized lipids and fatty acids [109, 110]. CD36 is extensively studied in atherosclerosis 
where the macrophages expressing CD36 binds and uptakes oxLDL, initiating the 
formation of atherosclerosis lesions [111]. CD36 is a major receptor for oxidized lipids in 
the eye, especially oxidized phospholipids. In the eye, CD36 is known to recognize shed 
photoreceptor outer segments [112, 113], oxidatively modified lipoproteins [114]. It has 
been shown that oxLDL is readily internalized by ARPE-19 cells via CD36 [115]. 
Moreover, a study in mice has shown that the uptake of oxLDL by RPE is CD36 
dependent [114] which suggests that CD36 plays an important role in clearing the 
oxidized lipids from Bruch’s membrane. 
 
 The other scavenger receptor of interest is CD5L/AIM which is also known as 
apoptosis inhibitor of macrophage. It is a 45kD secreted scavenger receptor which is 
identified as an apoptosis inhibitor that supports macrophage survival against apoptosis-
inducing stimuli [116]. CD5L/AIM circulates in the blood and is abundant around 5 
μg/ml in humans and around 2 μg/ml in mice [117]. In tissue macrophages, the 
transcription of CD5L/AIM is mediated by nuclear receptors LXR and RXR which 
protects macrophages from apoptosis [118]. In blood, the AIM proteins associate with 
IgM pentamers that protects the renal secretion of protein [119]. 
 
 CD5L is known to play a key role in atherosclerosis. CD5L/AIM is also known to 
be involved in the foam cells formation in macrophages [120]. Foam cells are fat laden 
macrophages that serve as hallmark of lesion formation in early stage of atherosclerosis. 
The uncontrolled uptake of modified LDL via scavenger receptors, impairment of 
cholesterol release mechanism and upregulation of esterification are some of the 
mechanism that triggers the formation of macrophage foam cells. In atherosclerosis 
lesions, CD5L/AIM promotes M2 macrophage polarization. It has also been shown that 
CD5L/AIM is one of the critical factors that protects the macrophages from oxLDL 
mediated apoptosis [116]. Furthermore, recent studies on macrophages demonstrated the 
involvement of CD5L/AIM in uptake of oxLDL via membrane bound CD36 scavenger 
receptor. However, the presence of CD5L/AIM in the retina and its contribution to 
oxLDL uptake is not known. Recently our group found that the sera of AMD patients 
have elevated CD5L/AIM circulating levels [121]. With these background information on 
the macrophages, and recent exciting findings from our lab provided us following 
research questions, a) to understand the significance of elevated CD5L/AIM 
autoantibodies in AMD patients, b) to elucidate the role of CD5L/AIM in uptake of 
oxLDL by RPE. 
 
 To answer above mentioned research questions, we set following central 
hypothesis, oxidized low density lipoprotein (oxLDL) is internalized by the RPE through 
the action of scavenger receptors CD36 and CD5L/AIM, and induces a cytoprotective 
molecular response in the RPE. To test this hypothesis we developed two specific aim for 
this study i) the transmembrane scavenger receptor CD36 binds oxLDL on the surface of 
RPE cells and mediates oxLDL uptake by the cells; ii) the RPE express and secrete the 
soluble scavenger receptor CD5L/AIM. We further postulate that CD5L/AIM present in 
the extracellular space binds oxLDL and facilitates its uptake (clearance) by the RPE, iii) 
the oxLDL uptake induces molecular response involving alterations of diverse pathways 
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and networks. To fully capture this response, we will use global-scale, discovery-based 




Materials and Methods 
 
 The immortalized human retinal pigment epithelium cells ARPE-19 were 
purchased from ATCC (Manassas, USA) and maintained in DMEM-F12 medium 
(ATCC, Manassas, USA) containing 2 mM L-glutamine supplemented with 10% fetal 
bovine serum (ATCC, Manassas, USA) 100 μg/ml antibiotic (Primocin, Invitrogen) in a 
humidified atmosphere with 5% CO2 at 37 ˚C. Primary human RPE cells, isolated 
postmortem as described [122, 123] were also obtained. Cells were grown to confluency 
in cell culture medium according to the same experimental protocol as ARPE-19 cells 
Exclusion criteria for human donor eyes included known retinal dystrophies, diabetic 
retinopathy, uveitis, trauma, prior retinal laser treatment, or other proliferative or 
degenerative retinal diseases. Primary cultures within the first ten passages were used. 
Antibody for CD5L (CD5L Antibody (F-1): sc-514283), GAPDH (GAPDH Antibody 
(0411): sc-47724) was purchased from Santa Cruz (Dallas, Texas).  IR-Dye labeled 
secondary antibodies (1 : 15 000 dilution; LiCor, Lincoln, Nebraska, USA) were used to 
detect primary antibodies. 
 
 
OxLDL Uptake by ARPE-19 Cells 
 
 ARPE-19 cells were grown in the coverslip. Cells were put on SFM for 24 hours 
before treating the cells with different concentration of DiI-oxLDL. 0.1, 0.5, 1, 2.5, 5, 
10ug/ml of oxLDL. After 5 h, the excess DiI-oxLDL was washed with PBS, fixed and 
coverslips were mounted on the glass slide. The images were taken with confocal 
microscopy. Image J software was used to quantify the red fluorescence in the cells. 
 
 
Western Blot Analysis 
 
 ARPE-19 cells were lysed, placed in reducing buffer containing β-
mercaptoethanol and heated at 95°C for 5 min. Samples were then run in by SDS–
polyacrylamide gel electrophoresis on BioRad (Hercules, California, USA). 15% gradient 
gels, and then transferred to nitrocellulose membrane using transblotter. The membranes 
were blocked in LiCor blocking buffer for 1 h at room temperature and probed with 
primary antibody in 0.1% Tween LiCor blocking buffer overnight at 4°C.  
 
 The membranes were washed three times for 10 min each in 0.01% Tween 
phosphate buffer solution then probed with IR-Dye labeled secondary antibodies in 0.1% 
Tween, 0.01% SDS LiCor blocking buffer for 1 h at room temperature. Washes were 
repeated after secondary labeling, washing three times for 10 min in Tween phosphate 
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buffer solution and then placed in water. The blots were scanned using the LiCor laser-
based image detection method. 
 
 
End-Point PCR for CD5L Determination 
 
 ARPE-19 cells were grown to confluency according to above mentioned 
conditions. Total RNA was isolated using the Qiagen RNA extraction kit with DNAse 
treatment according to the manufacturer's instructions (Santa Clara, CA).The total RNA 
was quantified by Nano Drop-ND 1000. The PCR amplification reaction (40 cycles) was 
performed using the following conditions: initial denaturation at 95 °C for 5 min, 95 °C 
for 30 s, 65 °C for 30 s and 72 °C for 1min. The following primer pairs were used: 5′- 
TGG GAC ATT AAG GAC GTG GC -3′ (forward) and 5′- CGG TCT CTG AAG GAG 
GGA GA -3′ (reverse) for CD5L/AIM, and 5′- ACC ACA GTC CAT GCC ATC AC -3′ 
(forward) and 5′- TCC ACC ACC CTG TTG CTG TA -3′ (reverse) for GAPDH. The 
PCR product was analyzed by agarose gel electrophoresis. After gel electrophoresis, the 
CD5L/AIM DNA band was cut from the gel and analyzed by DNA sequencing to 
confirm the expected CD5L/AIM transcript  
 
 
CD5L/AIM Binding Assay 
 
 5ug/ml of rhCD5L/AIM was coated on a 96 well plate overnight at 4 ˚C. The 
plate was then washed with fat free BSA for three times to remove the unbound 
rhCD5L/AIM. Next, DiI-oxLDL was added in triplicate in different concentrations for 4 
hours. The plate was then washed for two hours with fat free BSA. The DiI fluorescence 
was measured with the Cytation5 fluorescent reader with excitation wavelength 514 and 
emission 550. The binding constant was calculated using a graph pad prism. 
 
 
Cellular Uptake Assays of OxLDL by Confocal Microscopy and Flow Cytometry 
 
 ARPE-19 cells were grown in a 24 well plate until confluency. Cells were put on 
SFM for 24 hrs before treating them with 10ug/ml of DiI-oxLDL. After 5 hours, the 
excess DiI-oxLDL was washed with PBS, the cells were trypsinized and collected on 
PBS, and the uptake was analyzed with flow cytometer. For confocal microscopyARPE-
19 cells were grown in a 24 well plate until confluency. Cells were put on SFM for 24 h 
before treating them with 10ug/ml of oxLDL. After 5 h, the excess DiI-oxLDL was 




Blocking of CD36 Receptor for OxLDL Uptake Studies  
 
 ARPE-19 cells were grown in a coverslip. Cells were put on SFM for 24 h before 
pre-treating the cells with 100 μM of SSO for one hour. After the SSO treatment, the 
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cells were treated with 10ug/ml of DiI-oxLDL for 5 h. Next, the excess DiI-oxLDL was 
washed with PBS, fixed and coverslips were mounted on the glass slide. The images were 
taken with confocal microscopy. Image J software was used to quantify the red 
fluorescence in the cells. 
 
 
qPCR Analysis for OxLDL Mediated Gene Expression 
 
 ARPE-19 cells were grown in a 6 well plate until confluence. Cells were put on 
SFM for 24 h before the treatment with 100ug/ml of oxLDL/LDL for 4/24 h. The cells 
were then harvested for RNA extraction. qPCR analysis on genes of interest was 
performed using SYBR green assay using following primers: for LXRalpha, CCC CAT 
GAC CGA CTG ATG TT (forward), CGG AGG CTC ACC AGT TTC ATT (reverse); 
for CD36, GAG AAC TGT TAT GGG GCT AT (forward), TTC AAC TGG AGA GGC 
AAA GG(reverse); for G3PDH, ACC ACA GTC CAC GCC ATC AC (forward), TCC 
ACC ACC CTG TTG CTG TA (reverse); for CD5L GGC ATC GTG TGA GAA CCC 
AGA G(forward), CTC ACA CGA TGC CCC AGC ATC (reverse).  
 
 
Induction of CD5L/AIM with LXR-Agonist 
 
 ARPE-19 cells were grown in a 6-well plate until confluence. Cells were put on 
SFM for 24 h before the treatment with ug/ml of T090 for 24 h. The cells were then 
harvested for RNA extraction. qPCR analysis on ABCA1 {GCA CTG AGG AAG ATG 
CTG AAA (forward), AGT TCC TGG AAG GTC TTG TTC AC (reverse)} and 
CD5L/AIM was performed using the SYBR green assay. 
 
 
Cellular Uptake Assay of OxLDL by Flow Cytometry Using rhCD5L/AIM 
 
 ARPE-19 cells were grown in a 24 well plate until confluency. The cells were put 
on SFM for 24 h before treating the cells with DiI-oxLDL and rhCD5L/AIM. Cells were 
then treated with 0.1 ug/ml of DiI-oxLDL and 10ug/ml of rhCD5L/AIM. After 5 hours, 
the excess DiI-oxLDL and rhCD5L/AIM was washed with PBS, the cells were 





 Quantitative data are presented as mean ± standard error of the mean (SEM). All 
measurements were performed on triplicate samples. All experiments were conducted 




Results and Discussion 
 
 
ARPE-19 Cells Uptake OxLDL via CD36 
 
 To test the hypothesis that ARPE-19 cells uptake oxLDL, ARPE-19 cells were 
treated with DiI-oxLDL for 5 h. The excess oxLDL after the treatment was removed by 
washing. The cells were then fixed with PFA and then confocal images were taken 
(Figure 3-2A, B) by confocal microscopy. For flow cytometry, the cells were washed, 
trypsinized and the uptake was measured by flow cytometer (Figure 3-2C). For this 
experiment, DiI labeled oxLDL was used, and ARPE-19 cells were treated with 10ug/ml 
of DiI-oxLDL. Our results demonstrate that cultured RPE cells internalize oxLDL thus 
confirming similar findings by others [115, 124]. 
 
 To determine the role of the scavenger receptor CD36 in the uptake of oxLDL by 
ARPE-19 cells, prior to exposure to oxLDLwe treated the ARPE-19 cells with SSO 
which is a small molecule known to block CD36. The treatment of SSO for 1 h before the 
oxLDL treatment significantly reduced the uptake of oxLDL in ARPE-19 cells (Figure 
3-2B). The flow cytometry analysis of both the treated and untreated cells also showed 
similar result (Figure 3-2D). The results indicate that CD36 is the major receptors for 
oxLDL uptake by the ARPE-19 cells.  
 
 
 ARPE-19 Cells Express CD5L/AIM 
 
 The presence of CD36 in ARPE-19 cells was well-documented, however, the 
presence of CD5L/AIM was unknown until this study. We established the presence of 
CD5L/AIM in ARPE-19 cells by three different assays. It is noteworthy to mention that 
with all the experiments involving the CD5L/AIM, the cells were serum deprived at least 
for 24  h before any treatments to eliminate the cross contamination of  CD5L/AIM from 
bovine serum. The cellular localization of CD5L/AIM in ARPE-19 cells was confirmed 
by immunofluorescence assay. CD5L/AIM was present in the ARPE-19 cells both in 
cytoplasm and nucleus (Figure 3-3A, B). End-point PCR analysis was performed to 
validate the presence of CD5L/AIM transcript in ARPE-19 (Figure 3-3C). Moreover, 
CD5L/AIM protein level expression in both the ARPE-19 and primary RPE was 
determined by western blot analysis. Both the cell lines showed the presence of 
CD5L/AIM and the retinal pigment epithelial cell marker RPE65 (Figure 3-3D). Besides, 
the use of blocking peptide for the sequence of CD5L/AIM antibody diminished the 







Figure 3-2. oxLDL uptake by ARPE-19 cells. 
(A) Control (no treatment), (B) SSO treatment with DiI-oxLDL, (C) DiI-oxLDL only. 
Confocal Image: The ARPE-19 cells when treated with a small molecule SSO known to 
irreversibly block the CD36 receptors for one hour before adding the DiI labeled oxLDL 
for 5 h .The excess DiI-oxLDL was washed with PBS the cells were then fixed with 4% 
PFA and imaged with confocal microscope.(D) The blocking of CD36 caused significant 
decrease in oxLDL uptake Flow cytometry: ARPE-19 cells were treated with DiI-
oxLDL for 5 h .The excess DiI-oxLDL was washed with PBS the cells were trypsinized 
and collected in PBS. Fluorescence was measured by flow cytometry. Blocking of 
oxLDL uptake by SSO: The ARPE-19 cells when treated with a small molecule SSO 
known to irreversibly block the CD36 receptors for one hour before adding the DiI 
labeled oxLDL.. Mean fluorescence intensity ratio in cells scored in 10,000 cells were 
calculated by flow cytometer with three technical replicates from 3 independent 






Figure 3-3.  Expression of CD5L/AIM/AIM in the retinal pigment epithelium. 
(A) Confocal microscopy on immortalized human ARPE-19 cells. CD5L/AIM 
immunofluorescence is shown in green (blue, DAPI nuclear stain). Note the diffuse 
granular cytoplasmic reactivity seen in the ARPE-19 cells and the more discrete, clump-
like nuclear localization of the reactivity (see also magnified view in the inset in the top 
right hand corner, corresponding to the cropped area in A). (B) Negative control for 
ARPE-19 cells. Bar in A and B = 50 μm. (C) Results of end-point PCR demonstrate 
expression of the expected CD5L/AIM/AIM transcript in ARPE-19 cells, which was 
further confirmed by sequencing of the band (GAPDH, positive control; empty lane, 
negative control). (D) Results of Western blots performed on cell culture lysates of a 
primary human RPE cell line (hRPE) and an immortalized ARPE-19 cell line (green 
asterisk: CD5L/AIM/AIM band), confirming expression of CD5L/AIM/AIM also in both 
cell lines (red asterisk: RPE65 control band; last lane: human recombinant 
CD5L/AIM/AIM, positive control). (E) Confirmation of CD5L/AIM in ARPE-19 cells 
by using blocking peptide for the antibody against CD5L/AIM. 
 
Note: Panels A,B,C,D reprinted with permission from Elsevier Publications. Iannaccone, 
A., et al., Retinal pigment epithelium and microglia express the CD5 antigen-like protein, 
a novel autoantigen in age-related macular degeneration. Experimental Eye Research, 




Does CD5L/AIM Bind to OxLDL? 
 
 Interaction of CD36 with oxLDL and its uptake in ARPE-19 was studied in 
various studies [114, 125]. Since we wanted to explore the involvement of CD5L/AIM 
interaction with oxLDL and its uptake, we performed an ELISA assay where we coated 
the plate with rh CD5L/AIM and evaluated the binding of DiI-oxLDL with the rh-
CD5L/AIM. The binding affinity was calculated to be 13.6 kD by graph pad prism using 
‘one site-total and non specific binding’ equation (Figure 3-4A). We also transfected the 
ARPE-19 cells with CD5L/AIM and then treated the transfected cells with DiI-oxLDL. 
The confocal images show the co-localization of DiI-oxLDL particles (yellow dots) due 
to DiI-oxLDL (red) with CD5L/AIM (green) (Figure 3-4B). 
 
 
CD5L/AIM and CD36 Co-localize in the Presence of OxLDL 
 
 When ARPE-19 cells were treated with 100ug/ml of oxLDL for 4 h, co-
localization was observed between CD5L/AIM and CD36. This effect was not seen in the 
cells that were not treated with oxLDL. ARPE-19 cells were treated with 100ug/ml of 
oxLDL for 4 h and then the cells were washed and fixed with PFA. The cells were then 
incubated overnight with CD36 and CD5L/AIM antibody and then treated with suitable 
secondary antibody. The images were taken with confocal microscopy. The co-
localization of CD5L/AIM and CD36 was seen as yellowish orange dots in oxLDL 
treated cells (Figure 3-5). 
 
 
Effects of Anti-CD5L/AIM Antibody on OxLDL Uptake 
 
 To evaluate the effects of anti-CD5L/AIM antibody on the uptake of oxLDL by 
ARPE-19 cells, the cells were pre-treated with anti-CD5L/AIM antibody and IgG2A 
isotype control for 1 h at 37 ˚C. Then the cells were re-incubated for 5 h with DiI-oxLDL 
and anti-CD5L/AIM antibody and IgG2A for 5 h. After 5 h, the cells were washed and 
then the uptake was measured by flow cytometry. The oxLDL uptake due to anti-
CD5L/AIM treatments prior to and during the oxLDL treatment by ARPE-19 cells did 
not show significant change (Figure 3-6). 
 
 
CD5L/AIM, CD36 Expression Changes Due to OxLDL Treatment 
 
 Towards this aim, we treated the ARPE-19 cells with 100ug/ml for different time 
points, 4h and 24h. There was no significant difference between the expression of both 
the CD5L/AIM and CD36 at 4h. and 24h due to oxLDL treatment when normalized 








Figure 3-4. CD5L/AIM-OxLDL binding assay. 
(A) CD5L/AIM binding Assay (B) ARPE-19 cells were transfected with CD5L/AIM and 
then treated with DiI-oxLDL for 4 hours. The cells were washed, fixed and then confocal 
images were taken. The z-stack images show the co-localization of CD5L/AIM and 






Figure 3-5. Co-localization of CD36 and CD5L/AIM. 
(A) shows the oxLDL treated cells. (B) shows the cells that were not treated with oxLDL. 
The ARPE-19 cells were grown on coverslip until confluence. The cells were treated with 
100ug/ml of oxLDL for 5 hours after serum starving overnight. The cells were then fixed 
and stained for CD36 (green) and CD5L/AIM(red) and DAPI (blue). The overlap is 
indicated by red arrows The images were taken by confocal microscopy. At least three 






Figure 3-6. Effects of anti-CD5L/AIM antibody on the OxLDL uptake. 
ARPE-19 cells were grown to confluency and serum starved for 24 hours before treating 
them with anti-CD5L/AIM ab and IgG (isotype control). The ARPE-19 cells were then 
co-treated with DiI-oxLDL for 5 hours. There was a decrease in uptake due to anti-
CD5L/AIM antibody treatment, but it was not significant than the decrease due to isotype 






Figure 3-7. Effects of OxLDL on scavenger receptors. 
The ARPE-19 cells were treated with 100ug/ml of oxLDL for 4 and 24 h. The changes in 
the transcript of CD36, CD5L/AIM, were evaluated by SYBR-GREEN qPCR analysis. 
At least three biological replicate experiments were performed each with six technical 





Effect of LXR Agonist on Expression of CD5L/AIM 
 
 Since no significant blocking of oxLDL uptake was seen by the use of anti-
CD5L/AIM antibody, we wanted to investigate the effect of LXR agonist on the 
expression of CD5L/AIM. To demonstrate this effect, the ARPE-19 cells were grown to 
confluency and treated with T090 (LXR-agonist) for 24 hours and the expression of 
ABCA1 and CD5L/AIM was examined via sybr-green qPCR. The LXR agonist T090 is 
known to induce the expression of cholesterol efflux regulatory protein ABCA1. The use 
of LXR-agonist did not induce the expression of CD5L in ARPE-19 cells when 
normalized with the housekeeping gene GAPDH. However, significant induction was 
observed for ABCA1 gene (Figure 3-8). 
 
 
Recombinant CD5L/AIM (rh-CD5L/AIM) Effects the OxLDL Uptake by ARPE-19 
Cells 
 
 Since no significant blocking of oxLDL uptake was seen by the use of anti-
CD5L/AIM antibody, we wanted to investigate the effect of recombinant CD5L/AIM (rh 
CD5L/AIM) in oxLDl uptake by the cell lines. To this end, the cells were treated with 10 
μg/ml of rh-CD5L/AIM, and BSA as control along with 0.1 μg/mL DiI-oxLDL for 5 h at 
37 ˚C. Next, the cells were washed and collected for flow cytometry analysis. Our result 
showed that the addition of rh-CD5L/AIM along with DiI-oxLDL significantly decreased 
the amount of DiI-oxLDL within the ARPE-19 cells; (p-value 8.5499E-06) . However, 
control protein i.e. fat free BSA did not show significant decrease in mean fluorescence 
of oxLDL as shown in Figure 3-9.  
 
 Age-related macular degeneration is a complex multifactorial disease and 
formation of drusen is considered as the hallmark of the disease. Drusen is present 
between the retinal pigment epithelium and the Bruch’s membrane that consists of 
oxidized lipids and proteins. Moreover, these oxidized lipids accumulate preferentially in 
the macula of human eyes over age [126]. Since, RPE cells are the major player of lipid 
metabolism in the retina [127], the accumulation of lipids below RPE points towards the 
improper handling of lipids by these cells as we age. Also, AMD is similar to 
atherosclerosis where the retained lipoproteins are oxidized that induce a cascade of 
molecular events that eventually leads to the formation of atherosclerosis plaques. Hence 
in the similar manner, the accumulation of drusen containing oxidized lipids contributes a 
major factor in the development of AMD. 
 
 It is well-accepted that the accumulated oxidized lipids play a crucial role in the 
development of AMD. In addition, the retina is very vulnerable to oxidative stress. 
Furthermore, these oxidized lipids are identified by scavenger receptors present in the 
RPE cells which aid in clearance of oxidized lipids by these cells. With this important 
information generated by various studies, we investigated the effect of oxLDL on ARPE-
19 cells and elucidate the role of scavenger receptors CD36 and CD5L/AIM in retinal 






Figure 3-8. Effect of T090 on ARPE-19 cells. 
ARPE-19 cells were treated with T090. The expression of CD5L/AIM and ABCA1 was 
measured by qPCR.There was significant induction of ABCA1 gene due to LXR-agonist 






Figure 3-9. Effect of rh-CD5L/AIM on OxLDL uptake. 
ARPE-19 cells were grown to confluency and serum starved for 24 hours before treating 
them with rh-CD5L/AIM and BSA (control protein) and DiI-oxLDL for 5 hours. There 
was a significant decrease in mean fluorescence for DiI-oxLDL due to rh-CD5L/AIM 
treatment. Figure shows mean fluorescence intensity ratios in 10,000 cells with three 




not induce cell death. In contrast, when the cells were treated for 24 h, 20% of cell death 
was observed. Since we wanted to observe the role of scavenger receptors and its effect 
on oxLDL treated ARPE-19 cells, we choose 4 h time point where there was no cell 
death. 
 
 To elucidate the role of CD36 and CD5L/AIM in oxLDL uptake by ARPE-19 
cells, we first demonstrated by confocal microscopy and flow cytometry that the oxLDL 
is indeed up taken by ARPE-19 cells. Similarly, we demonstrated that ARPE-19 cells 
uptake oxLDL, which was primarily dependent on CD36. CD36 is a primary scavenger 
receptor that is expressed in numerous cell types including RPE and other cells of the 
immune system such as macrophages, microglia, etc. In a recent study on ARPE-19 cells, 
the use of an anti CD36 antibody (that blocked the CD36 receptor) in the presence of 
oxLDL has shown concentration dependent decrease in uptake of oxLDL by the cells 
[125]. In our study, we used a small molecule sulfo-N-succinimidyl oleate (SSO), a 
potent CD36 binding inhibitor [128]. The pre-treatment of ARPE-19 cells by SSO 
significantly decreased the uptake of DiI-labeled oxLDL in the cells, thus indicating that 
CD36 is a major receptor responsible for internalization of oxLDL by RPE.  
 
 CD5L/AIM was another scavenger receptor of our interest since our recent study 
on the autoantibodies expressed in AMD patient sera had shown an increase in 
CD5L/AIM autoantigen in the diseased population [121]. We also determined the 
presence of CD5L/AIM in ARPE-19 cells by various independent experiments which 
provided us a baseline to build up our experiments. Before investigating the role of 
CD5L/AIM in the uptake of oxLDL, it was important to determine the binding of 
CD5L/AIM and oxLDL  in-vitro. The affinity of oxLDL with rh-CD5L/AIM was 
reported in a recent study by ELISA [120]. In this study, we demonstrated that 
CD5L/AIM binds oxLDL in-vitro.. The cells that were transfected with CD5L/AIM 
(green) and treated with DiI-oxLDL (red) showed co-localization of CD5L/AIM and DiI-
oxLDL. Moreover, the CD5L/AIM and CD36 were seen to co-localize in the presence of 
oxLDL. The CD5L/AIM and CD36 axis in the uptake of oxLDL by macrophages has 
been reported by other groups [120]. 
 
 CD5L/AIM is known to play a major role in atherosclerosis, a disease which is 
considered mechanistically close to AMD [129]. Also, it is known to be involved in 
macrophage survival and foam cell formation [120, 130]. In macrophages, the activation 
of LXR/RXR nuclear receptor by LXR agonist induces the expression of CD5L/AIM 
which protected macrophages from bacteria-induced apoptosis [131, 132].However, our 
results did not show the change in CD5L/AIM and CD36 in the transcript or protein level 
due to 4 h of oxLDL treatment. The use of anti-CD5L/AIM did not affect the oxLDL 
uptake by ARPE-19 cells when compared with the isotype control.  
 
 Recently published work on acute kidney injury in mice showed that circulating 
CD5L/AIM helped in the removal of intraluminal debris along with KIM-1 (kidney 
injury molecule-1) [133]. Since our data on blocking the CD5L/AIM by anti CD5L/AIM 
antibody present in ARPE-19 cells did not show significant effect on oxLDL clearance 
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by the cells, measured as the amount of oxLDL accumulated within the cells, we were 
interested to see the effect of adding external CD5L/AIM on the oxLDL clearance by the 
ARPE-19 cells. For this, we used recombinant CD5L/AIM (rh-CD5L/AIM) and 
incubated the cells with DiI-oxLDL in the presence of rh-CD5L/AIM. Our results 
showed a significant reduction of intracellular oxLDL accumulation in ARPE-19 cells in 





 Our results demonstrated a new dynamics on CD5L/AIM on oxLDL uptake that 
was not seen in macrophages. The reduction in intracellular accumulation of oxLDL due 
to the presence of extracellular recombinant CD5L/AIM is an interesting phenomenon as 
it has been recently shown the involvement of CD5L/AIM in autophagy [133]. It would 
be interesting to know how the CD5L/AIM impacts the oxLDL clearance by the cells. 
One explanation for our findings is that, CD5L/AIM blocks the uptake of oxLDL and 
alternative explanation is that CD5L/AIM aids in early intracellular degradation and 
clearance of oxLDL by ARPE-19 cells. For this, the use of an antibody that could bind to 
the rh-CD5L/AIM or IgM which is known to bind to the CD5L/AIM could help elucidate 
the mechanism. Second, a time-course study of oxLDL clearance in the presence of 
CD5L/AIM encompassing early time points would illuminate whether CD5L/AIM 
prevents oxLDL uptake or whether CD5L/AIM facilitates intracellular degradation of 
oxLDL. If CD5L/AIM promotes intracellular clearance of oxLDL, we would expect that 
at early time points of oxLDL exposure, presence of CD5L/AIM would not cause a major 
difference in oxLDL accumulation but that over time, there would be a reduction in the 
accumulation of intracellular oxLDL, as we observed at the single time point examination 
(after 5 h exposure) presented here. Finally, the use of autophagy inhibitor along with rh-
CD5L/AIM would validate the role of rh-CD5L/AIM in oxLDL degradation by ARPE-19 







CHAPTER 4.    EARLY TRANSCRIPTOME ALTERATIONS INDUCED BY 





 Age related macular degeneration (AMD) is the leading cause of legal blindness 
in the Western world [134]. The pathogenesis of AMD is not fully understood, with age 
being the major risk factor, some genetic determinants and environmental factors are 
known to play an important role in the progression of the disease [135-138]. Oxidative 
stress and inflammation are considered as main events leading to the pathophysiology of 
the disease [139]. The retinal pigment epithelium (RPE), the principal tissue affected in 
early stage AMD, is considered a major site of oxidative stress in the retina due to its 
location: between the photoreceptor outer segments, exposed to photo oxidative light 
energy, and the choroid with high oxygen content. In this study, we focused on oxidized 
low-density lipoprotein (oxLDL), which is a major component of drusen and a known 
inducer of cellular oxidative stress with pro-inflammatory properties [140]. OxLDL 
generates from low-density lipoprotein (LDL) in a pro-oxidant tissue environment in 
which lipids and proteins become oxidatively modified [94] It comprises a heterogeneous 
group of macromolecular complexes consisting of various classes of oxidized lipids 
associated to native or oxidized apolipoprotein B (apoB). As stated in previous chapter 
oxidation-specific epitopes (OSEs) enable recognition of oxLDL by cellular and soluble 
pattern recognition receptors (PRRs) that mediate clearance of oxLDL as part of a 
protective response by the innate immune system to maintain cellular homeostasis [95]. 
The response of ARPE-19 cells to oxidative stress induced with various agents has 
previously been reported. Weigel et al. analyzed the transcriptome alteration in ARPE-19 
cells after a 4 h exposure to various pro-oxidizing agents including H2O2, 4-
hydroxynonenal and tert-butylhydroperoxide [141]. Cano et al. performed a 
transcriptomics analysis of ARPE-19 cells exposed to cigarette smoke extract (CSE) 
[142]. Similarly to the study presented here, Koller et al. used transcriptomics analysis of 
RAW 264.7 macrophages after a 4 h exposure to oxidized phospholipids, which are 
common constituents of oxLDL [143]. Yamada et al. studied the effects of oxLDL 
induced oxidative stress in ARPE-19 cells and focused on the cellular response after 48 h 
treatment [124]. To obtain a comprehensive outlook of the early transcriptome alterations 
induced by oxLDL exposure, we performed microarrays gene expression analyses in 
ARPE-19 cells following a 2 and 4 h treatment with non-lethal doses of oxLDL. We 
report that various gene pathways including genes involved in anti-oxidative defense 
mechanisms, circadian rhythm regulation, and lipid metabolism are induced in a time-
dependent and selective fashion by oxLDL treatment. Gene expression changes as an 
early response to oxLDL treatment in RPE cells could help to better understand the early 
molecular events in the pathogenesis of AMD and decipher the role of oxidative stress to 




Materials and Methods 
 
 
Cell Culture and RNA Preparation  
 
 The immortalized human retinal pigment epithelium cells ARPE-19 were 
purchased from ATCC (Manassas, USA) and maintained in DMEM-F12 medium 
(ATCC, Manassas, USA) containing 2 mM L-glutamine supplemented with 10% fetal 
bovine serum (ATCC, Manassas, USA) 100 μg/ml antibiotic (Primocin, Invitrogen) in a 
humidified atmosphere with 5% CO2 at 37 ˚C. For the cytotoxicity assay cells were 
grown in 96-well plates in serum-containing medium. Before LDL or oxLDL treatment, 
the cells were grown in serum-free medium for 24 h followed by addition of oxLDL or 
LDL (0-800 μg/ml). After 24 h treatment, 50 μl of the medium was transferred to a fresh 
96-well flat clear bottom plate for measurement of lactate dehydrogenase (LDH) release 
with CytoTox 96® according to manufacturer’s recommendations. The plates’ 
absorbance at 490 nm was measured with Bio Tek Synergy 2 fluorescence reader. The 
EC50 value was calculated with Prism v. 7.0 (GraphPad). All experiments were 
performed in multiple biological replicates (n = 4). OxLDL (TBARS: 29-44 nmoles 
MDA/mg) and LDL were obtained from Alfa Aesar (Tewksbury, USA). Cells (150,000) 
were seeded on 6 well plates and grown until confluent. Serum-starved (24 h) ARPE-19 
cells were treated with 100 μg/ml of oxLDL and 100 μg/ml of LDL for 2 h and 4 h, 
respectively. All experiments were performed in multiple biological replicates (n = 6). 
Total RNA was extracted with the Qiagen RNeasy mini kit after DNAse treatment, and 
RNA quality and quantity were validated with the Agilent Bio Analyzer microfluidics 
chip RNA Nano 6000. Samples were stored at -80 ˚C until further use. 
 
 
Microarray Analysis  
 
 RNA samples were analyzed with an Affymetrix Human Clariom S array using 
Affymetrix WT Plus Amplification kit according to manufacturer’s protocols. Arrays were 
washed and stained on Affymetrix Fluidics Station 450 and scanned on Affymetrix Scanner 
GCS3000. Data were normalized using the Affymetrix Expression Console. The DEGs 
were determined based on fold change (FC) and Benjamini-Hochberg adjusted false 
discovery rate (FDR). Cutoffs values of |FC| > 1.5 and FDR ≤ 5% were selected. 
 
 
Bioinformatics Analysis  
 
 Transcripts that were significantly up or down regulated were analyzed with 
DAVID [144] and Ingenuity Pathway Analysis (IPA) software ((Ingenuity Systems Inc., 
Redwood City, CA) and STRING [59]. DAVID generates a group of gene clusters, from 
a supplied gene list, using an algorithm such that the genes in a cluster have similar 
biological meaning or function. Due to few expression changes observed with LDL 
treatment, we focused on analyzing the biological processes that were altered by the 
oxLDL treatment by choosing “GOTERM_BP_ALL” as a data source. The functional 
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annotation clusters use the kappa statistics (measure the degree of the common genes 
between two annotations), which give clusters of annotated terms that share common 
genes by using medium classification stringency. Annotation clusters were pooled from 
both the upregulated and downregulated list and only enriched terms with FDR<20% 
were interpreted with reflected biological processes. 
 
 
qPCR Analysis  
 
 cDNA was prepared from the isolated mRNA (1μg) by reverse transcription using 
random hexamers and Maxima H Minus reverse transcriptase according to the 
manufacturer’s recommendations (Thermo Fisher Scientific ). Real time qPCR analyses 
were performed using gene specific primers and Power SYBR™ Green PCR Master Mix 
(4367659) with a StepOnePlus SYBR green system (Applied Biosystems).Primers used 
are: HMOX1, AGA CTG CGT TCC TGC TCA ACA T(forward), GGG GCA GAA TCT 
TGC ACT TTG T(reverse); GCLM, CAT TTA CAG CCT TAC TGG GAG G (forward), 
CGT GCG CTT GAA TGT CAG G (reverse); NQO1, AAA AGA AGC TGG AAG CCG 
CA (forward), AGG ATT TGA ATT CGG GCG TC(reverse) ; HMGCR, TCA AAG 
GGT ACA GAG AAA GCA C(forward), TAT GCT CCC AGC CAT GGC AG(reverse); 
ABCA1, GCA CTG AGG AAG ATG CTG AAA(forward), AGT TCC TGG AAG GTC 
TTG TTC AC(reverse); LDLR, CTG GAC CGG AGC GAG TAC AC (forward), TGG 
GTG CTG CAG ATC ATT CTC (reverse); SQLE, TGG GCA TTG CCA CTT TCA 
C(forward), GGC CTG AGA GAA TAT CCG AGA AG(reverse); BHLHE40, AAT 
CAT TGC CCT GCA GAG TG(forward), CGA AGA CTT CAG GTC CCG 
AG(reverse); PER1, CTG CTA CAG GCA CGT TCA AG(forward), CTC AGG GAC 
CAA GGC TAG TG(reverse). Briefly, the reaction mixture consisted of 10 ng cDNA, 0.6 
μM primers in a final volume of 50 μl reaction mixture. Each cycle consisted of a 
denaturation step at 95 ˚C for 15 seconds, annealing and extension steps at 55 ˚C for 1 
min for a total of 40 cycles. A melt curve was generated for each reaction to confirm the 
absence of non-specific amplification products. GAPDH was used for normalization. All 




Results and Discussion 
 
 Accumulation of oxLDL is believed to contribute to the pathogenesis of AMD by 
establishing a low-grade, chronic inflammatory state in the macula. The molecular 
mechanisms that link the accumulation of oxLDL to the development of AMD are poorly 
understood. Recent studies in primary human fetal RPE (hf-RPE) suggest that oxLDL-
induced cytotoxicity requires binding through the CD36 cellular scavenger receptor and 
the activation of the NLRP3 inflammasome [145].  In agreement with this and other 
studies, e.g. [146], we determined that CD36 is a major contributor to the cellular uptake 
of oxLDL in retinal pigment cells: a drastic decrease of oxLDL uptake was observed as 
measured by quantitative flow cytometry or confocal microscopy imaging analysis 
following pretreatment of cells with the CD36-specific irreversible inhibitor sulfo-N-
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succinimidyl oleate (SSO) [147] (Figure 3-2A and B). To allow for the detection of a 
robust and early gene expression response without significant cytotoxicity, various 
exposure times and oxLDL concentrations were tested. We established that 2 h and 4 h 
treatment of ARPE-19 cells with 100 μg/ml of oxLDL had no detectable cytotoxicity as 
measured by the LDH cytotoxicity assay (Figure 4-1). Cell treatment with 100 μg/ml of 
oxLDL for 2 and 4 h triggered a reproducible, robust gene expression response as shown 
by Pearson’s Correlation in Figure 4-2.  
 
 To determine the specificity of the oxLDL-triggered gene expression changes in 
the cells, they were also treated for 4 h with 100 μg/ml of LDL, the non-oxidized form of 
oxLDL. The microarray data showed a marked difference in gene expression profiles 
between the LDL and oxLDL treatment. The 4h oxLDL treatment caused the highest 
number of differentially expressed genes: 727 genes were differentially expressed as 
compared to controls, whereas the LDL treatment caused expression changes in 241 
genes. Only 32 genes were commonly up- or down-regulated between the two treatment 
groups (FDR < 5 %, fold change ≥ 1.5) (Figure 4-3A). The oxLDL-induced change in 
gene expression was time dependent, with an increase in the number of differentially 
expressed transcripts at 4 h (Figure 4-3B). Interestingly, the data showed that in response 
to 4 h oxLDL treatment the largest number of differentially expressed genes were down-
regulated (Figure 4-3C), even though the transcripts with the largest changes in 
expression were up-regulated genes (Figure 4-4A). 
 
 A heat map of the differentially expressed genes (FDR < 5 % and fold change ≥ 
2.0) provides an overall view of the effects of the different treatments: (i) oxLDL 
triggered a much stronger transcriptomics response than LDL; (ii) the oxLDL effects 
were time-dependent and much more pronounced after 4 h treatment (Figure 4-4B). 
Analysis of the 4 h oxLDL-induced DEGs (FDR < 5 %, fold change ≥ 2.0) by DAVID 
functional annotation tool identified 53 annotation clusters for the up regulated gene 
transcripts and 73 for the down regulated ones, respectively. Selected enriched annotation 
clusters with statistically significant annotation terms (Benjamini < 0.005) with 
associated biological processes are shown in Figure 4-5. 
 
 The analysis of the up-regulated gene transcripts identified functional annotation 
term clusters that contain elements relevant to anti-oxidative stress response, among 
others, while analysis of the down-regulated transcripts identified functional annotation 
term clusters including ones that contain elements that are relevant to lipid biosynthesis 
and circadian rhythm regulation. Gene expression changes of selected elements from the 
identified functional annotation term clusters from DAVID analysis at 4 h oxLDL (FDR 
< 5 %, fold change ≥ 2.0), and the corresponding changes observed at 2h oxLDL are 
shown in Table 4-1. Gene expression results observed for the 4 h LDL treatment (FDR < 
5 %, fold change ≥ 2.0) are summarized in Table 4-2. Taken together, the data shown in 
Table 4-1 and 4-2 demonstrate the time-dependency and selectivity of the gene 
expression response. 
 
 To validate the microarray results, selected transcripts were quantified by qPCR. 





Figure 4-1. Cytoxicity of OxLDL in ARPE-19 cells. 
ARPE-19 cells were treated with 10 different concentration of oxLDL for 4 h and 24 h. 
After treatment, the medium from each well was collected, and cytotoxicity was 





Figure 4-2. OxLDL for 2 and 4 h triggered a reproducible, robust gene expression 
response. 








Figure 4-3. Gene expression changes caused by oxLDL and LDL treatment. 
(A): Venn diagrams illustrating the common and unique genes expressed by LDL and 
oxLDL treatment at 4 h and (B) 2h and 4h (fold change > 1.5, FDR < 5 %). (C). Bar 
graph showing the number of up- and down-regulated genes due to each treatment at 2 h 





Figure 4-4. Volcano plot and heat map for mRNA expression. 
(A) Scatter-plot of the mean expression fold-changes versus significance. Left, down-
regulated; right, up-regulated genes. The red dashed lines represent the threshold limits 
for statistical significance (p = 0.05). (B) Heat map for a set of genes with fold changes ≥ 







Figure 4-5. Molecular networks and pathways. 
(A) STRING gene interaction network. Selected significantly enriched biological 
processes are highlighted with colored circles. (B) Selected functional clustering results 
by DAVID. Gray bars: biological processes down-regulated by oxLDL; red bars: 
processes up-regulated by oxLDL. (C) STRING gene interaction network encompassing 
members of Nrf2-controlled oxidative stress response. Bioinformatics analyses were 
carried out for a set of differentially expressed genes with more than 1.8 fold change 




Table 4-1. Gene expression changes due to oxLDL at 2 h and 4 h. 
 
Pathways/Genes 2 h OxLDL/Con 4 h OxLDL/Con 
Response to oxidative stress   
 HMOX1 129.6 624.7 
 SLC7A11 6.1 52.0 
 GCLM 3.1 9.6 
 GCLC 1.2 3.5 
 NQO1 1.7 3.4 
 SRXN1 1.7 2.8 
 TXNIP 1.8 2.7 
 HSPA1B 1.6 2.3 
 CYP1B1 1.6 2.1 
 CYP1A1 -1.0 2.4 
Lipid metabolism   
 ABCA1 1.1 2.0 
 ACSS2 -1.0 -2.0 
 SC5D -1.4 -2.0 
 MSMO1 -1.2 -2.3 
 SPTLC2 -1.9 -2.3 
 HSD17B7 -1.4 -2.5 
 ACACA -1.3 -2.5 
 MVK -1.3 -2.6 
 FASN -1.4 -2.7 
 IDI1 -1.3 -2.8 
 SQLE -1.4 -3.2 
 INSIG1 -1.7 -4.7 
 HMGCS1 -1.8 -10.2 
 HMGCR -2.6 -12.6 
 LDLR -2.0 -12.7 
Circadian rhythm   
 ID3 2.2 5.2 
 ID2 1.4 2.5 
 PPARGC1A 1.6 2.2 
 PHLPP1 -1.2 -2.0 
 NRIP1 -1.4 -2.2 
 KLF9 -0.7 -2.5 
 ETS1 -1.6 -2.7 
 ID1 -1.2 -2.8 
 KLF10 -1.1 -3.7 
 EGR1 -1.9 -7.9 
 PER1 1.0 -1.8 





Table 4-2. Gene expression changes due to LDL at 4 h. 
 
Pathways / Genes 4 h LDL/Con 
Response to oxidative stress  
HMOX1 3.6 
Lipid metabolism 
 FAXDC2  2.1 
 HMGCS1 -2.0 
 HMGCR -2.1 
Other 
 PORCN  2.3 
 EHD3  2.0 
 SIGMAR1  2.0 
 CDC42  -2.1 
 NUDT6  -2.2 
 PPM1B  -2.6 





oxidative stress response, lipid metabolism and circadian rhythm processes. The qPCR 
results were consistent with the microarray data Table 4-3. 
 
 
OxLDL and Anti-Oxidative Stress and Inflammatory Response 
 
 Ingenuity pathway analysis (IPA) of this group of up regulated genes identified 
the nuclear factor erythroid 2–related factor 2 (NRF2) transcription factor as the main 
regulatory element of the antioxidant response. Age-related macular degeneration (AMD) 
manifests with the formation of drusen, originating from cellular and inflammatory debris 
that accumulates between the retinal pigment epithelium (RPE) and the Bruch’s 
membrane. Impairment of the innate immune response, high fat/cholesterol diet and 
oxidative stress play a role in the onset and development of AMD. The retina is very 
vulnerable to oxidative stress: it has a high metabolic rate, high oxygen tension, high 
content of polyunsaturated fatty acids (PUFAs), the presence of retinal pigments and has 
exposure to light. All these factors contribute to the presence of a highly oxidative 
cellular and tissue milieu in which DNA, lipids, and proteins become oxidized. The 
molecular and cellular mechanisms that lead from oxidative stress to cell dysfunction, 
cell death, and tissue damage are poorly understood. To date, the strongest 
epidemiological evidence indicates two main risk factors for AMD: (i) genetic 
polymorphism in genes involved in complement regulation and (ii) environmental 
factors, i.e., cigarette smoking. Oxidative stress, specifically protein oxidation and its 
deleterious consequences on cell viability, is sufficient to mechanistically account for 
both observations. Weismann et al. demonstrated this clearly by showing a mechanistic 
link between CFH polymorphism, the highest genetic risk for developing AMD, and 
oxidative stress-induced protein modification [148]. To counter the damaging effects of 
protein oxidation, the RPE cells have developed numerous anti-oxidant protective 
mechanisms. One central component of the protective network is nuclear factor 
erythroid-2 related factor 2 (NRF2), which in the presence of intracellular reactive 
oxygen species (ROS), induces the expression of various detoxifying enzymes including 
enzymes of the glutathione redox system, catalases (CAT), superoxide dismutases 
(SOD), and the aldehyde dehydrogenases (ALDH). The NRF2-mediated transcription 
regulation is a well characterized anti-oxidative response mechanism (Batliwala, Xavier 
et al. 2017), which involves, the release of the inactive Nrf2 protein from its interaction 
with Kelch-like ECH-associated protein 1 (Keap1), translocation to the nucleus and 
dimerization with Maf proteins, binding to the antioxidant response element (ARE) 
located in the promoter region of target genes and initiation of transcription.  
 
 One of the target genes known to be up-regulated by the activation of Nrf2 during 
the acute phase of an anti-oxidative response is HMOX1. Kronke et al., have shown that 
the increase of protein levels of heme oxygenase 1 (HO-1) in human umbilical vein 
endothelial cells following treatment with oxidized 1-palmitoyl-2-arachidonoyl-sn-
glycero-3-phosphorylcholine (OxPAPC), a component of oxLDL, in addition to NRF2 
transcription activation, involves the activation of the cAMP-responsive element-binding 




Table 4-3. Validation of gene expression changes by qPCR.  
 
Gene 2 h OxLDL/Con 4 h OxLDL/Con 4 h LDL/Con 
HMOX1 34.3*** 175.7*** 11.9*** 
GCLM 4.4*** 12.6*** 1.8** 
NQO1 2.0*** 6.8*** 1.1 
HMGCR -2.3** -7.9*** -5.1*** 
ABCA1 1.3*** 2.1*** 1.9*** 
LDLR -1.2* -4.7*** -5.4*** 
SQLE -1.2*** -2.3*** -2.1*** 
BHLHE40 -2.1* -15.9*** 1.0* 




Note: *p< 0.05; **<0.01;***p<0.001 (n=6 biological replicates) 
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kinase p38 and ERK [149]. These findings, suggest that cellular anti-oxidative stress 
responses to oxidized phospholipids require the activation of multiple signaling cascade 
pathways that lead to a strong up-regulation of HO-1. 
 
 In agreement with above mentioned studies, Ingenuity Pathway Analysis (IPA) of 
our transcriptomics data clustered several of the most up-regulated genes around the 
NRF2 transcription factor (Figure 4-5C). Within this cluster of up-regulated transcripts, 
HMOX1 had the highest up-regulation at 2 and 4 h oxLDL treatment (> 129 and 600-fold 
increase, respectively) in entire data set. HO-1 catalyzes the breakdown of heme into 
biliverdin, iron and carbon monoxide [150]. It is up-regulated in chronic and acute 
inflammation [151, 152] and it has anti-oxidative stress and anti-inflammatory properties 
[153, 154]. Interestingly, polymorphism of the HMOX1 gene, which results in an aspartic 
acid to histidine substitution at position 7 in the protein, has been shown to be associated 
with increased susceptibility to dry AMD [155]. In addition to HMOX1, treatment of 
ARPE-19 cells with oxLDL also induced a strong NRF2-dependent up-regulation of 
other gene transcripts, whose translation products have anti-oxidative enzymatic activity 
including: GCLM (Glutamate-Cysteine Ligase Modifier Subunit), NQO1 (NAD(P)H 
dehydrogenase [quinone] 1), GSR (Glutathione-Disulfide Reductase), GCLC (Glutamate-
Cysteine Ligase Catalytic Subunit), CAT (Catalase) and FTL (Ferritin Light Chain).  
 
 Studies have shown the essential role of immunity or inflammatory factors 
involved in the development and progression of AMD [1, 156, 157]. oxLDL is known to 
induce inflammatory responses in various tissue types [158-160]. Moreover, one of the 
most cytotoxic components of oxLDL, 7-ketocholesterol, is known to activate 
inflammatory responses in the ARPE-19 cells [161-163]. Ingenuity pathway analysis 
(IPA) of our transcriptomics data identified a set of genes involved in inflammatory 
responses that were up-regulated following the 2 h treatment with oxLDL including 
CEBPB (CCAAT/Enhancer Binding Protein Beta), IL1RN (Interleukin 1 Receptor 
Antagonist), JAK2 (Janus kinase 2) , CXCL8 (Interleukin 8), IL6R (Interleukin 6 
receptor) and IL1RL1 (Interleukin 1 Receptor Like 1). CEBPB is a well characterized 
transcription factor that regulates the expression of genes involved in immune responses 
[164]. Similar to our study, CEBPB has been shown to be up-regulated in RPE cells 
following the treatment with agents known to cause oxidative damage - homocysteine 
[165] and N-(4-hydroxyphenyl) retinamide (4HPR) a retinoic acid derivative that causes 
oxidative damage through the generation of reactive oxygen species (ROS) [166].  
 
 
OxLDL and Circadian Rhythms 
 
 The photoreceptors shed their outer (POS) segment tips daily through cellular 
processes dependent on light conditions [167] and the RPE play a critical role in 
removing the aged POS tips through phagocytosis, a process synchronized with the POS 
shedding and controlled by circadian rhythm mechanisms [168, 169]. In fact, there is a 
strong link between ocular physiology and circadian rhythm with the circadian 
rhythmicity of the RPE playing a critical role for the support of the photoreceptors and 
retinal function [170] in all vertebrate animals, including humans [171]. Phagocytosis in 
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RPE is known to increase ROS production, which can alter the renewal process such as 
delayed termination of shedding or defect in RPE digestion and can cause accumulation 
of lipofuscin [172]. The accumulation of lipofuscin is one of the major risk factors 
associated with macular degeneration [173, 174]. However, the mechanistic links 
between phagocytosis of POS, accumulation of ROS and lipofuscin, dysfunction of the 
circadian rhythm and AMD onset and development are poorly understood [175]. Various 
studies have shown that disruption of circadian rhythm promotes inflammation in mice as 
well as in humans [176-178], and disruption of circadian rhythmicity in the retina results 
in increased retinal inflammation in a diabetic mouse model [179]. Moreover, mouse 
treated with dexamethasone and triamcinolone acetonide, powerful anti-inflammatory 
agents, caused up-regulation of genes involved in circadian rhythm regulation one week 
after treatment [180]. Since oxLDL is a well-known pro-inflammatory agent, its effects 
on circadian rhythm genes may be consequent to an early inflammatory response.  
 
 A novel gene pathway affected by oxLDL-induced oxidative stress was 
uncovered by our study and relates to the regulation of gene transcripts known to 
participate in circadian rhythm mechanisms Table 4-1. All circadian rhythm-associated 
transcripts were down regulated, and the down regulation was observed only in the 4 h 
treatment group suggesting a time delay between treatment and response. The most down 
regulated gene was the class E basic helix-loop-helix protein 40 (BHLHE40), a 
transcriptional repressor involved in the regulation of the circadian rhythm. Other down 
regulated genes were kruppel-like factor 9 and 10 (KLF9 and KLF10). KLF9 is a 
circadian transcription factor that regulates cell proliferation. KLF10 is a transcriptional 
repressor that binds to the GC box sequence in the promoter sequence of the ARNTL 
(BMAL1) clock component and represses its transcriptional activity. Also, as a result of 
the oxLDL 4h treatment, we observed a down regulation of the period circadian protein 
homolog 1 transcript (PER1), a core component of the circadian clock. The mammalian 
cellular circadian molecular system consists of core clock genes Period (PER) 1 and PER 
2, cryptochrome (CRY) 1 and CRY 2, CLOCK, and Arntl or BMAL1 ( Aryl hydrocarbon 
receptor nuclear translocator like) genes [181]. These genes generate circadian rhythm 
through coupled transcription/translocation feedback loops [180]. The CLOCK and 
BMAL1 form the transactivating, i.e., the positive components of the feedback loop and 
PER and CRY the transinhibitory, i.e., the negative components [182].  
These results suggest a potential role of oxLDL in the inhibition of the RPE phagocytic 
and metabolic clearing processes through interference with circadian rhythm related 
molecular processes. How the uptake of oxLDL might interfere with circadian rhythm 
processes remains to be further investigated. Nevertheless, based on our data and 
published literature, we propose a molecular mechanism that could explain the observed 
down regulation of circadian rhythm transcripts by oxLDL, which involves the activation 
of the aryl hydrocarbon receptor (AhR) by oxidized lipid or protein components of 
oxLDL. Activation of AhR can induce two separate transcription pathways [183]: 1. 
Activated AhR binds to ARNT and induces xenobiotic metabolism through binding to 
dioxin response elements (DREs) and transcription of genes with detoxifying functions 
such as cytochrome P450, family 1, member 1A (Cyp1A1). Our data shows up regulation 
of Cyp1A1. 2. Activated AhR binds to Bmal1 and prevents its binding to Clock thus 
inhibiting the formation of the Bmal1-Clock heterodimer essential for the transcription of 
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circadian genes, which are needed for phagocytosis. In support of our working 
hypothesis, our data show a down regulation by oxLDL of major circadian genes 
including Per1, BHLHE40, and KLF10 (Figure 4-6). 
 
 
OxLDL and Autophagocytosis 
 
 The 4 h oxLDL treatment induced the up-regulation of the autophagy inducer 
sequestosome1 (p62/SQSTM1). The p62 is one of the most important genes involved in 
regulating the packing and transporting of ubiquitinated, misfolded and aggregated 
proteins for clearance via autophagy in mammalian cells [184]. Under oxidative stress 
conditions, induction of the p62 gene is regulated by NRF2 and contributes to activation 
of NRF2-controlled target genes through a positive feedback loop that enhances the 
cellular anti-oxidative stress response that includes the degradation and removal of the 
NRF2 inhibitor KEAP1 protein via autophagocytic mechanisms [185]. In RPE cells, it 
has been shown that p62 plays a central role in improving cellular viability when the 
proteasomal pathways are disrupted due to oxidized protein aggregates [186]. Studies in 
other cell types have shown that p62/SQSTM1 positively regulates NOD2-induced 
overexpression of genes related to inflammation such as tumor necrosis factor alpha 
(TNF-α) and interleukin-1β (IL-1 β) [187]. Our transcriptomics studies confirm that 
oxLDL induces the p62-KEAP1-NRF2 stress response axis in ARPE-19 cells [185].  
 
 
OxLDL and Lipid Metabolism  
 
 The accumulation of lipids and lipid derivatives in the sub retinal space and the 
association of genes involving lipid metabolism such as APOE (apolipoprotein E), CETP 
(cholesteryl ester transfer protein), LIPC (hepatic lipase gene) and LPL (lipoprotein 
lipase) with AMD, provides support for the postulated role lipids play in the pathogenesis 
of AMD [188-191]. In our study, we found 62 genes involved in lipid metabolic 
pathways that were differentially expressed in the 4 h oxLDL treatment group. 
 
 The highly down-regulated group of transcripts included genes involved in fatty 
acid synthesis such as FASN (fatty acid synthase), BDH1 (3-hydroxybutyrate 
dehydrogenase 1), ACACA (acetyl-CoA carboxylase alpha), HSD17B7 (hydroxysteroid 
17-beta dehydrogenase 7), IDI1(isopentenyl-diphosphate delta isomerase 1), the 
transcriptional activator required for lipid homeostasis SREBF1 (sterol regulatory 
element binding transcription factor 1), as well as the LDL receptor, low density 
lipoprotein receptor (LDLR), which had a 12 fold decrease in expression as compared to 
the control cells. In contrast, the lipid efflux gene ABCA1 involved in cholesterol efflux 
was up-regulated. 
  
 Excess intracellular cholesterol is known to suppresses the formation of new low-
density lipoprotein receptor (LDLR) and cholesterol synthesis [192]. In agreement with 












with LDL, had a major impact on the expression of genes whose protein products 
regulate lipid and steroid metabolism. Interestingly, following a 4 h treatment with 
oxLDL, the most down regulated transcript in the entire data set was LDLR. LDLR is a 
cell membrane-bound protein receptor responsible for the uptake of LDL, but not oxLDL. 
The down regulation of the LDLR receptor occurs in response to the intracellular release 
of the oxLDL lipid cargo, which include cholesterol and triglycerides. The increase of the 
intracellular levels of cholesterol and triglycerides triggers signaling mechanisms that 
result in the down regulation of gene transcripts whose protein products are enzymes 
involved in the uptake of extracellular LDL and the de-novo synthesis of cholesterol. In 
addition to strong down regulation of LDLR, our data shows a significant down 
regulation of 3-hydroxy-3-methylglutaryl-CoA (HMGCR), 3-hydroxy-3-methylglutaryl-
CoA synthase 1 (HMGCS1) and other gene transcripts part of the cholesterol synthetic 
pathway. The HMGCR protein product is the rate-limiting enzyme in the synthesis of 
cholesterol and nonsterol isoprenoids, while the HMGCS1 transcript codes for another 
enzyme part of the cholesterol biosynthetic pathway. Expression of LDLR, HMGCR, and 
HMGCS1 is regulated by the sterol regulatory element-binding protein 1 (SREBF1) 
transcription factor, also significantly down regulated in the 4 h oxLDL treatment group. 
In contrast to the strong down regulation of gene transcripts whose protein products 
regulate cholesterol and lipids uptake and de novo synthesis, our data show significant up 
regulation of gene transcripts whose products are involved in cholesterol and lipids 
degradation and cellular efflux. In this functional group of gene transcripts up regulated 






 The significant differences observed in the gene transcription response to oxLDL 
versus LDL treatment confirm the ability of the ARPE-19 cells to recognize and react to 
oxidation specific epitopes (OSE) present on LDL (i.e., oxLDL). Furthermore, due to the 
OSE heterogeneous nature, different cellular defense mechanisms are activated, some 
that have the Nrf2 as the major transcription factor, other AhR, PPARG, etc.while the 
non-OSE containing LDL component of oxLDL induces the expression of genes that 
mediate the down regulation of gene pathways involved in lipid metabolism and lipid 
synthesis.  These results depict a complex cellular and molecular mechanism, which 
involve various pathways only partially overlapping. The oxLDL treatment caused 
differential expression of genes involved in oxidative stress, lipid metabolism, 
inflammation, autophagy, and circadian rhythm; all of these pathways are known to be 
involved in the pathogenesis of AMD. While the earlier studies on the oxLDL induced 
transcriptome alteration on ARPE-19 were conducted at longer time points, our study 
shows the early events that occur in the ARPE-19 cells as they are exposed to oxLDL. 
Understanding the early molecular pathways that are regulated due to the exposure of 
oxLDL in the ARPE-19 cells line can provide us insight on early mechanisms going in 
the retinal pigment epithelium cells due to the presence of oxidized lipids in the retina. 
These findings then could give us targets to intervene the pathogenesis for AMD 
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CHAPTER 5.    PROTEOMIC ANALYSIS OF OXLDL TREATED ARPE-19 





 Proteomics global-scale examination of the structure and function of proteins 
[14]. The study of proteins is crucial to understanding the pathological condition of 
various diseases as these are the key players in the metabolic pathways within the cells 
[193]. The importance of understanding the molecular mechanism of biological processes 
in human diseases has been strengthened by the establishment of biology and disease 
driven human proteome project (B/D-HPP) [194]. The B/D-HPP focuses on in-depth 
characterization and quantification of proteins by utilizing the state of art proteomics 
tools. This has enormously helped biological sciences and clinical community to better 
understand the molecular mechanism underlying various biological processes relevant to 
human diseases. With this regard, the human eye proteome project was started in 2013 
with the goal to gather better insight on the disease mechanism in various parts of the 
eyes [195]. 
 
 The main aims of the differential proteomic approaches are to obtain a better 
mechanistic understanding of biological processes in various contexts, to identify new 
drug targets, and to improve the diagnosis of disease via biomarker discovery [196]. The 
proteomic field can be divided into two main analytical flows, top-down and bottom-up, 
based upon the protein or peptide characterization. The top-down proteomics is the 
analysis of proteins by mass spectrometer without proteolytic digestion. Although the 
top-down proteomics has its advantages and limitations when compared to the bottom-up 
approach, however, the later has been increasingly adopted in proteomics. In our study, 
we have also applied the bottom-up approach to characterize the differential proteome. 
Hence, I discuss the bottom-up approach below in detail.  
 
 In the bottom-up approach, the proteins from any biological system are extracted 
and digested with proteolytic enzymes such as trypsin, which will yield a mixture of 
peptides. The peptides are then separated by chromatography and analyzed by mass 
spectrometer. The sample acquisition by mass spectrometer can be done by three 
different approaches. The first approach is the data-dependent acquisition (DDA) based 
approach in which first full MS scan is recorded for all the ions that co-elute at a given 
point in the gradient elution. Then the mass spectrometer chooses a specific number of 
the most abundant precursor ions after which the MS/MS scans of the fragments from the 
selected precursor ions are recorded. The instrument hence switches between the full scan 
acquisition and the fragment ion acquisition. The DDA method is one of the best 
established strategies in the field of bottom-up proteomics [197].  
 
 The second approach is data-independent acquisition (DIA), in which both the 
entire range of ions that co-elute at a given point in the gradient elution and the fragment 
ions (for all parent ions) are acquired. The peptide fragmentation information is then 
retrieved by two methods: i) by generating the pseudo fragment ion spectra that are 
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constructed from the DIA data obtained, ii) by target signal extraction on the basis of 
previously acquired single peptide fragmentation spectra. One of the major advantages of 
DIA over DDA is that in DIA the entire range of possible precursor ions and their 
fragment ions can be analyzed unlike in DDA where only selected precursor ions are 
fragmented [198].  
 
 The third approach in bottom-up proteomics is the targeted proteomics. Unlike 
DIA and DDA, in this case, the protein of interest is already known. In targeted 
proteomics, only a small set of predetermined and previously identified peptides based on 
their m/z and elution time are selected. These preselected specific peptides of interest are 
then applied to the MRM (Multiple Reaction Monitoring) or PRM (Parallel Reaction 
Monitoring) experiments. In MRM, a subset of the preselected ion from each MS1 scan is 
selected to be fragmented and measured in the MS2 scan.  In PRM, however, all the ions 
of preselected precursor ions are measured [199]. 
 
 The discovery-based proteomics utilizing mass spectrometry can be either 
quantitative or qualitative. The quantitative proteomics utilizes protein identification 
methods similar to the qualitative proteomics (as discussed in chapter 2) except that it 
includes an additional quantification step. The quantitative proteomics provides 
physiological differences between two biological samples. The quantitative analysis can 
be done in two ways: i) stable isotope labeling and ii) label free quantification. The 
majority of quantitative proteomic analysis is done using the stable isotope labeling. 
Various isotope labeling techniques include isotope-coded affinity tags (ICAT), isobaric 
tags for relative and absolute quantification (iTRAQ), isobaric labeling (tandem mass 
tags (TMT), SILAC (stable isotope labeling by amino acid in cell culture) and 18O[200]. 
It labels the protein either during the cell growth or during sample preparation. The 
labeling changes the molecular mass but does not change the chromatographic and mass 
spectrometric behavior. The difference in peak area between the labeled and unlabeled 
peptides then is used to determine the quantitative difference.  
 
 Isotope labeling is a complex process that is time consuming and expensive [201]. 
In recent years, label free approaches are constantly being developed. Among the 
numerous label free methods, quantitation based on peptide spectral counting [202] and 
peptide ion peak area [203] are extensively applied. In the spectral counting label-free 
quantification approach, peptides are quantified based upon m/z, peak area, and retention 
time for each ion in all experiments. In label free quantification based upon peptide ion 
peak area, peak intensities of MS signals are integrated across retention time at a defined 
mass window known as the area under the curve (AUC) or extracted ion chromatography 
(XIC) [204]. 
 
 In this project, I applied a state-of-the-art mass spectrometer from Waters “The 
Synapt G2 Si”. We planned to use the SDS-PAGE based platform for analyzing the 
differentially expressed proteome for this study as described in chapter 2. Since, in this 
study we wanted to analyze the differentially expressed (i.e quantitative analysis) proteins 
in oxLDL treated cells the sample throughput was greater than the earlier study in which 
we only performed qualitative analysis. However, our lab acquired a new high resolution 
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mass spectrometer within the span of four years which is better than the low resolution 
mass spectrometer (LTQ) that we used earlier. Waters Q-TOF is a hybrid analyzer which 
gives outstanding peak definition and accurate mass measurement of peptides as it 
provides highest dynamic mass resolution. Together with UPLC and MSE, the Synapt G2 
Si acquires data which contains a complete time resolved record of all detectable 
precursor and product ions. Nano UPLC enables the nano scale separation of complex 
tryptic digest with maximum resolution, speed, and sensitivity. UPLC utilizes sub 2 μm 
chromatographic particle which can operate in 6000-15000 psi. The instrument uses the 
extra dimension of ion mobility separation that maximizes separation, selectivity, and 
confidence. Triwave high efficiency ion mobility separates ions on the basis of size, 
shape, and charge before transferring to Q-TOF for high resolution mass analysis. In Q-
TOF mass analyzers the quadrupole is operated as ion guide in MS mode and mass 
selection device in MS/MS mode. The ions are then accelerated by an electric field and 
m/z is determined by TOF [205]. Moreover, the additional dimension of ion mobility 
separates ion with the same mass providing greater analytical peak capacity. High 
chromatographic resolution is essential for achieving high coverage and mass spectral 
data quality (Figure 5-1). Data independent MSE is a revolutionary technique for data 
acquisition. It acquires all possible analytes simultaneously between high and low 
collision energy during a single chromatographic run [201]. 
 
 As mentioned in Chapter 3, Age related Macular Degeneration (AMD) is one of 
the leading causes of vision loss affecting 30 million individual worldwide that includes 
10 million elderly Americans [1]. With no FDA approved drugs available for the 
treatment of dry AMD and no adequate treatment options available for wet AMD, there is 
a dire need to better understanding the disease mechanism to intervene the disease 
progression. This has directed the scientific community towards the study of the disease 
progression of dry AMD at the molecular level. Various studies have also shown that 
oxidation of the lipids and lipoproteins contributes to the RPE death, suggesting the role 
of oxidative stress in the pathogenesis of AMD [126, 206, 207]. To this end, we used the 
oxidized lipoprotein (oxLDL) in the human ARPE-19 cells and accessed the differential 
proteome alteration due to its treatment to better interrogate the proteins alterations and 
interactions for understanding the molecular mechanism of AMD.  
 
 Differential proteomic analysis of ARPE-19 cells treated with other oxidative 
stress causing agents such as cigarette smoke extract (CSE), advanced glycation end 
products (AGEs) and photocoagulation has been studied earlier. A study involving the 
treatment of ARPE-19 cells with AGEs utilized 2D gel electrophoresis for protein 
separation, gel image analysis, and LC-MS/MS to identify the differentially expressed 
proteins [208]. Another study utilized label free quantification with LC-MS/MS to 
identify differentially expressed proteins due to CSE treatment [209]. Recently, Agardn 
et al. studied differential proteomic analysis on ARPE-19 cells due to photocoagulation 
[cite]. They utilized IEF for separation, iTRAQ for labelling and LC-MS/MS for 












 We described early transcriptome alteration due to oxLDL treatment in the 
previous chapter. However, no proteomic study has been done in the context of oxLDL, 
which is one of the components of drusen. It would be interesting to interrogate the 
proteome alteration and compare it to the transcriptome alterations due to oxLDL 
treatment. Therefore, in this study, we interrogated the proteome alteration in ARPE-19 
cells due to oxLDL treatment. We used a bioanalytical platform that uses a high-
resolution mass spectrometer in a data independent setting to analyze the peptides 
obtained from treated and untreated cells. The platform incorporated a nano UPLC for the 
separation of peptides in combination with LC-MS/MS.  
 
 





 The immortalized human retinal pigment epithelium cells ARPE-19 were 
purchased from ATCC (Manassas, USA) and maintained in DMEM-F12 medium 
(ATCC, Manassas, USA) containing 2 mM L-glutamine supplemented with 10% fetal 
bovine serum (ATCC, Manassas, USA) and 100 μg/ml (Invitrogen, Carlsbad, USA) in a 
humidified atmosphere with 5% CO2 at 37 °C. 
 
 
OxLDL Treatment and Sample Collection 
 
 Cells (150,000) were seeded in 6 well plates and grown until confluent. Serum-
starved (24 h) ARPE-19 cells were treated with 100 μg/ml of oxLDL and 100 μg/ml of 
LDL for 4 h. All experiments were performed in multiple biological replicates (n = 5). 
After 4 h of treatment, the cells were washed with PBS, collected and stored in liquid 
nitrogen until further processing. 
 
 
Sample Preparation for Mass Spectrometry 
 
 The samples were proteolyzed with trypsin and Lys-C (iST 8x kit, Preomics, 
Germany) using a sample preparation protocol provided by the manufacturer [211]. 
Briefly, the cell samples were lysed using lysis buffer, which denatures, reduces and 
alkylates proteins, for 10 min at 95 ˚C. Then the samples were digested using digest 
buffer that had trypsin and Lyc-C mixture at 37 ˚C for 3 h. The digestion was stopped 
with stop buffer and then the samples were washed with wash solutions to remove 
hydrophobic and hydrophilic contaminants. The peptides were then finally eluted from 
cartridge with elution solution. Finally, the peptides were re-suspended on the LC-Load 







 Samples were analyzed by a Waters Synapt G2Si mass spectrometer system with 
a nanospray ion source interfaced to a Waters Acquity M-class UPLC system (C18 
reversed-phase capillary column). Each sample was spiked with internal standards to 
determine the amount of protein on the column. All peptide separations were performed 
on a nanoUPLC liquid chromatography system (Waters Acquity M-class UPLC system). 
Mobile phase A was H2O containing 0.1 % formic acid; mobile phase B was ACN 
containing 0.1 % formic acid. Peptide samples were injected in a volume of 2 μl using 
partial loop injection, onto a Symmetry C18, 5 μm, 180 μm x 20 mm trap column 
(Waters). After pre-concentration, the peptides were eluted from the trap column to the 
analytical column, HSS T3 C18, 1.8 μm, 75 μm x 250 mm (Waters), and separated with a 
gradient of 2-40 % mobile phase B over 180 min at a flow rate of 0.3 μl/min. The column 
temperature was maintained at 45 °C. The eluted peptides were analyzed on-line on a 
Synapt G2-Si (Waters Corporation) high-resolution ion mobility mass spectrometer 
(IMS). The lock mass peptide [Glu1]-fibrinopeptide B was delivered by infusion through 
the instrument fluidics system. It was used to improve the mass accuracy of the analysis.  
The quadrupole RF was set for efficient transmission of ions with m/z of 300-2000. Data 
was acquired in a data-independent acquisition (DIA) mode with ion mobility separation 
and optimized transfer collision energy, ultra-definition MSE (UDMSE) [212]. The TOF 
(Time-of-Flight) analyzer was operated in resolution mode (resolution ≥ 20,000 FWHM, 
with the average mass error of 5 ppm or less), a scan time of 0.6 ms, MSE range 50-2000 





 The data was imported with the file format (.raw) from Synapt G2Si Mass 
Spectrometer and analyzed by Progenesis QI software 
(http://www.nonlinear.com/progenesis/qi-for-proteomics/download/). Oxidation of 
methionine was included as variable modification and, carbamidomethyl modification of 
cysteine was specified as fixed modification. Trypsin was specified as a protease with 
maximum of one missed cleavage allowed. The ion matching requirement selection was 
1 or more for fragment/peptides, 3 for fragment/proteins and 1 for peptides/protein. The 
data was also searched against decoy database, and the false discovery rate was set to 4% 
at the peptide level. Peptides were selected based on the significance measures, e.g., 
ANOVA p-value and fold change. Identified proteins were displayed according to the 
protein grouping method, which is based on a less stringent application of the parsimony 
principle. The differentially expressed proteins were determined based on fold change 





 The differentially expressed protein list was analyzed online using STRING and 
DAVID software [213]. After the proteins are identified by the protein search databases 
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and tools, bioinformatics tool PANTHER was used to characterized identified proteins 
according to cellular, molecular and biological categories [56]. 
 
 
Results and Discussion 
 
 In this study, we performed qualitative and quantitative analyses of ARPE-19 
cells. For the quantitative proteomic analysis, the cells were treated with oxLDL. 
OxLDL, known to exert oxidative stress, is present in drusen, the hallmark of AMD. 
Oxidative stress is considered as one of the major contributing factors for the 
pathogenesis of AMD. Therefore, the proteomic changes that occur in the ARPE-19 cells 
due to oxLDL are of great importance in understanding the molecular mechanism of 
oxLDL induced oxidative stress. To this end, we performed an in-depth differential 
proteomic analysis for oxLDL induced proteome alteration in human ARPE-19 cell lines. 
The ARPE-19 cells were grown to confluence and treated with 100 μg/ml of oxLDL and 
LDL for 4 h. The cells were then collected, and performed single-step lysis, denaturation, 
alkylation and reduction with Preomics kit as manufacturer recommendations, to obtain a 
complex mixture of trypsin and Lys-C digested peptides. The peptide mixtures were 
separated with reverse phase nanoUPLC system from Waters Corporation. The separated 
peptides were then analyzed online on a Synapt G2-Si (Waters Corporation) high-
resolution ion mobility mass spectrometer (IMS). The data from the mass spectrometer 
was analyzed by Progenesis software to get the list of total proteins identified by this 
analytical platform and the list of differentially expressed proteins due to LDL and 
oxLDL treatments. The summary of the experimental approach to characterize the 
oxLDL induced proteome alteration in ARPE-19 cells is illustrated in Figure 5-2. 
 
 As we mentioned in Chapter 2, global scale examination of proteome in any 
biological system is extremely challenging, and no single analytical technique is capable 
of identifying and characterizing proteome complexity. Hence, we presented, in Chapter 
2, the evaluation of three different bioanalytical platforms in terms of extent and depth of 
proteome coverage. Among the platforms evaluated, we found SDS-PAGE based 
platform performed the best as it identified around 900 proteins with wide abundance 
level. In addition, the workflows utilized the old, low resolution LTQ instrument. Also 
the pre-fractionation step in the SDS-PAGE based platform where we analyzed 15 
fractions per sample becomes time and resource consuming if we need to study 
differential protein expressions. As the study of differential proteomics needs analysis of 
multiple replicates which drastically increases the throughput.  
 
 In this study, we utilized a high resolution mass spectrometry combined with 
nano-UPLC in a data independent setting. This platform provided a better proteome 
coverage which identified around 2500 proteins, i.e., around 3-fold more proteins than 
the SDS-PAGE based analytical platform. Even though this new analytical platform does 
not include any pre-fractionation step, the use of nano-UPLC, state-of-the-art mass 
spectrometer with ion mobility, and data independent acquisition provided us better 








provides nano scale separation with high resolution whereas the extra dimension of ion 
mobility separation maximizes separation and selectivity. Moreover, the data independent 
MSE acquisition provides the ability to analyze all possible analytes and label free 
quantification of differentially expressed proteins. These combinations make the new 




Protein Identification and Expression Profile 
 
 RPE is a monolayer of polarized cells which is an integral part of blood retinal 
barrier. They play an important role in maintaining retinal hemostasis and in survival of 
photoreceptors. Proteomic studies of RPE would provide a great insight in better 
understanding its function in diseased and healthy conditions. In our study, 17189 unique 
peptides were identified which corresponded to 2485 proteins with 2 or more than 2 
unique peptides. The identified proteins were then classified per their cellular 
components, molecular functions, and biological processes by PANTHER [62]. 
PANTHER classification of the expressed proteins according to biological processes, 
classified the proteins into 13 groups as shown in Figure 5-3A. The largest group of 
proteins was cellular processes which included 1131 proteins and contained proteins 
involved in cell communication (244), cell cycle (116), cellular component movement 
(52), cytokinesis (23) and growth/proliferation (5). Metabolic processes included 954 
proteins. Most of these proteins fell under the subclass of primary metabolic processes 
(843) and biosynthetic process (95). Cellular component organization and biogenesis was 
the third largest group with 430 proteins. Localization with 335 proteins included 
proteins involved in transport. A subclass response to stress, the major subclass under 
response to stimulus, included 74 proteins. Immune system processes included 33 
proteins. 
 
 According to the molecular processes, PANTHER classified the expressed 
proteins into 9 groups as shown in Figure 5-3B. The catalytic activity included the 
largest group of proteins (705), which consist of following sub-groups: transferase 
activity (154), oxidoreductase activity (118), hydrolase activity (317), and enzyme 
regulator activity (59). These groups of molecular processes are important for RPE-
functions. The second largest group was binding (669). Most of the proteins in this group 
fell under carbohydrate binding (2), chromatin binding (18), nucleic acid binding (232), 
nucleotide binding (37), antigen binding (1), lipid binding (14), protein binding (382), 
calcium-dependent phospholipid binding (3), and calcium ion binding (38).  
 
 One of the most important functions of RPE is to provide nutrients to the 
photoreceptors, and thus the proteins corresponding to this function were expected at the 
output. The bioanalytical platform used in this study, in fact, was able to identify 17 
lipids and phospholipids binding proteins. Also, the other groups such as structural 
molecule activity (173), transporter activity (106), signal transducer activity (47), 
receptor activity (41), translation regulator activity (31), antioxidant activity (16), and 
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Figure 5-3. Gene ontology categorization of the identified proteins according to (A) biological process, (B). molecular functions 
and (C). cellular components. 
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channel regulator activity (1) are important in RPE functions. In addition to housekeeping 
genes, a number of proteins known to be associated with RPE functions are identified in 
this study. RPE cells are the most phagocytic tissue present in humans as they 
phagocytize the shed outer segment tips from photoreceptors daily. Proteins involved in 
macromocular degradations such as cathepsin B, Z, D, and L1 were also observed in the 
result. Furthermore, RPE is rich in reactive oxygen species due to active phagocytosis 
and photooxidative environment. As expected, the proteins with antioxidant activity are 
identified and are listed in Table 5-1. 
 
 PANTHER classified the identified proteins according to cellular component into 
8 groups which are shown in Figure 5-3C. The groups were cell part (1018), organelle 
(730), macromolecular complex (490), membrane (294), cell junction (37), extracellular 
matrix (15), and extracellular region (39). RPE monolayer is an integral part of blood 
retinal barrier, and the integrity of the RPE is critical for retinal function [214]. Proteins 
corresponding to this are also identified. Specifically, 37 junctional proteins are identified 
which are important for RPE functions. One of the proteins identified in this study is 
prominin1 which is a cholesterol binding protein, and mutated prominin1 is known to be 
present in patient with macular degeneration [215, 216]. 
 
 
Differential Proteomic Profiling Due to OxLDL Treatment 
 
 The distribution of unique proteins identified in each treatment and the overlap 
between all the three individual treatments are shown in Figure 5-4. It is noteworthy that 
even with a large number of proteins identified with the state-of-art high-resolution mass 
spectrometer, there was a significant overlap among the identified proteins due to the 
treatments. Specifically, there were 2527 proteins commonly identified in all the 
treatments, and 83, 196 and 192 proteins uniquely identified in control, LDL and oxLDL 
treatments respectively. 
 
 The oxLDL treatment significantly (p=0.05) changed the expression of 80 
proteins, and among them, 41 proteins were increased/decreased by more than 1.5-fold 
due to the treatment. The list of genes with their known function is listed in Table 5-2. 
 
 Among the 41 genes, 19 were up-regulated, and 22 were down-regulated. 
Interestingly, the oxLDL treatment induced the 3.5-fold increase in the expression of 
HMOX1 which is one of the important components of anti-oxidation system in ARPE-19 
cells. The samples were assayed for the upregulation of HMOX1 transcript before 
performing the proteomic studies on the oxLDL, and LDL treated samples by qPCR. The 
oxLDL treated samples showed around 40-fold increase and the LDL treated samples 
showed around 3 fold increase in HMOX1 expression. These results were in line with the 
transcriptomic data presented in the previous chapter. The other upregulated proteins 
mostly belong to cell survival, solute carriers. Programmed cell death protein 10 is 
upregulated important for stability of KDR/VEGFR2. VEGFR2 is under investigations 




Table 5-1. Proteins involved in antioxidant activity. 
 
S.N. Accession Number Protein Description 
1 P32119 Peroxiredoxin-2 
2 Q16881 Thioredoxin reductase 1, cytoplasmic 
3 P78417 Glutathione S-transferase omega-1 
4 P30044 Peroxiredoxin-5, mitochondrial 
5 P30041 Peroxiredoxin-6 
6 P04179 Superoxide dismutase [Mn], mitochondrial 
7 P30048 Thioredoxin-dependent peroxide reductase, mitochondrial 
8 P00441 Superoxide dismutase [Cu-Zn] 
9 P07203 Glutathione peroxidase 1 
10 Q92626 Peroxidasin homolog 
11 Q06830 Peroxiredoxin-1 
12 O14880 Microsomal glutathione S-transferase 3 
13 P04040 Catalase 
14 Q8TED1 Probable glutathione peroxidase 8 
15 Q13162 Peroxiredoxin-4 







Figure 5-4. Venn diagram of proteins identified in ARPE-19 cells with control, 
LDL and oxLDL treatments. 
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condition Description Functions 
Q8N1V2 5 25.1 0.00138 5.8 oxLDL Cilia- and flagella-associated protein 52 May play a role in cell growth and/or survival 
P09601 11 101.4 7.30E05 3.5 oxLDL Heme oxygenase 1  Exhibits cytoprotective effects  
P22735 2 9.5 0.04250 2.5 oxLDL Protein-glutamine gamma-
glutamyltransferase K  
Involved in cell proliferation  
Q6ZU15 4 24.7 0.00201 2.1 oxLDL Septin-14  --- 
Q96H55 3 16.4 0.02799 2.0 oxLDL Unconventional myosin-XIX  It is involved in mitochondrial motility. 
Q9BUL8 8 51.0715 0.04763 1.9 oxLDL Programmed cell death protein 10  Promotes cell proliferation. Modulates 
apoptotic pathways. Increases MAPK activity 
and STK26 activity.  
Q99969 3 17.7399 0.00498 1.8 oxLDL Retinoic acid receptor responder protein 
2  
Regulates adipogenesis, metabolism and 
inflammation 
Q14094 4 18.0393 0.02893 1.7 oxLDL Cyclin-I  --- 





0.00531 1.7 oxLDL Unconventional myosin-Vb  May be involved in vesicular trafficking via the 
CART complex that is necessary for efficient 
transferrin receptor recycling 
Q06520 3 15.9978 0.03649 1.7 oxLDL Bile salt sulfotransferase  Acts as sulfonate donor to catalyze the 
sulfonation of steroids and bile acids in the liver 
and adrenal glands  
P34059 6 32.1681 0.04384 1.6 oxLDL N-acetylgalactosamine-6-sulfatase  --- 
O75027 2 10.3521 0.05771 1.6 oxLDL ATP-binding cassette sub-family B 
member 7_ mitochondrial  
Plays a central role in the maturation of 
cytosolic iron-sulfur (Fe/S) cluster-containing 
proteins. 
P49736 13 78.4186 0.00474 1.5 oxLDL DNA replication licensing factor MCM2  Acts as component of the MCM2-7 complex 
(MCM complex) for DNA replication initiation 
and elongation in eukaryotic cells. 
P46783 12 79.0937 0.03512 1.5 oxLDL 40S ribosomal protein S10  --- 
P54802 12 81.2849 0.03310 1.5 oxLDL Alpha-N-acetylglucosaminidase  Involved in the degradation of heparan sulfate. 
Q08209 8 41.0657 0.03026 1.5 oxLDL Serine/threonine-protein phosphatase 2B 




Table 5-2. (Continued.) 











condition Description Functions 
Q9BVP2 18 98.075 0.04319 1.5 oxLDL Guanine nucleotide-binding protein-like 
3  
May be required to maintain the proliferative 
capacity of stem cells.  
Q9Y2V2 1 6.639 0.05232 1.5 oxLDL Calcium-regulated heat-stable protein 1  Binds mRNA and regulates the stability of 
target mRNA. Binds single-stranded DNA (in 
vitro) 
O75844 6 35.4133 0.04309 3.1 Controls CAAX prenyl protease 1 homolog Proteolytically removes the C-terminal three 
residues of farnesylated proteins. 
Q13526 5 27.5287 0.041241 2.7 Controls Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1  
Regulates mitosis presumably by interacting 
with NIMA and attenuating its mitosis-
promoting activity.  
Q5TF21 4 26.0579 0.004162 2.7 Controls Protein SOGA3  --- 
P55011 6 28.7042 0.014657 2.4 Controls Solute carrier family 12 member 2  Mediates sodium and chloride reabsorption. 
Plays a vital role in the regulation of ionic 
balance and cell volume. 
Q5T7M9 5 31.696 0.030891 2.2 Controls Protein FAM69A  --- 
Q96G01 26 149.339
4 
0.045389 2.2 Controls Protein bicaudal D homolog 1  Regulates coat complex coatomer protein I 
(COPI)- independent Golgi-endoplasmic 
reticulum transport by recruiting the dynein-
dynactin motor complex. 
Q6IPM2 7 45.8517 0.022053 2.1 Controls IQ domain-containing protein E  --- 
P18827 2 11.8076 0.033626 2.1 Controls Syndecan-1  Regulates exosome biogenesis in concert with 
SDCBP and PDCD6IP. 
Q9H4A6 6 34.4795 0.042464 2.0 Controls Golgi phosphoprotein 3  Phosphatidylinositol-4-phosphate-binding 
protein that links Golgi membranes to the 
cytoskeleton  
Q9BQE5 5 29.7731 0.016539 2.0 Controls Apolipoprotein L2  May affect the movement of lipids in the 
cytoplasm or allow the binding of lipids to 
organelles  
Q96KN1 7 51.3589 0.022464 1.5 Controls Protein FAM84B  --- 
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Table 5-2. (Continued.) 











condition Description Functions 
Q5T200 17 91.7961 0.027959 1.9 Controls Zinc finger CCCH domain-containing 
protein 13  
Acts as component of the WTAP complex that 
is involved in RNA processing and cell cycle 
Q8NFU7 2 11.8539 0.034706 1.9 Controls Methylcytosine dioxygenase TET1  Plays a key role in active DNA demethylation.  
Q8TES7 2 9.115 0.034421 1.7 Controls Fas-binding factor 1  Keratin-binding protein required for epithelial 
cell polarization. Involved in apical junction 
complex (AJC) assembly via its interaction 
with PARD3. Required for ciliogenesis 
Q9H3P7 15 84.7999 0.033429 1.7 Controls Golgi resident protein GCP60  Involved in the maintenance of Golgi structure 
by interacting with giantin, affecting protein 
transport between the endoplasmic reticulum 
and Golgi. 
Q9Y697 7 36.5836 0.029239 1.7 Controls Cysteine desulfurase_ mitochondrial  Catalyzes the removal of elemental sulfur from 
cysteine to produce alanine. It supplies the 
inorganic sulfur for iron- sulfur (Fe-S) clusters.  
Q8NDZ4 10 55.4458 0.012477 1.6 Controls Deleted in autism protein 1  May play a role in cardiomyocyte proliferation 
through paracrine signaling and activation of 
the PPI3K-AKT-CDK7 signaling cascade 
P61513/A
6NKH3 
2 12.164 0.052936 1.5 Controls 60S ribosomal protein L37a  --- 
O43264 11 57.0269 0.023874 1.5 Controls Centromere/kinetochore protein zw10 
homolog  
Essential component of the mitotic checkpoint, 
which prevents cells from prematurely exiting 
mitosis 
Q86YR7 13 70.7216 0.004251 1.5 Controls Probable guanine nucleotide exchange 
factor MCF2L2  
--- 
Q8IWB7 15 89.8162 0.043805 1.5 Controls WD repeat and FYVE domain-containing 
protein 1  
Positively regulates TLR3- and TLR4-mediated 
signaling pathways. Promotes TLR3/4 ligand-
induced activation of transcription factors IRF3 
and NF-kappa-B, as well as the production of 
IFN-beta and inflammatory cytokines. 
Q96IZ0 7 41.9123 0.043278 1.5 Controls PRKC apoptosis WT1 regulator protein  Pro-apoptopic protein capable of selectively 





protein is also induced by due to oxLDL treatment which plays role in inflammation 
through activation of the chemokine-like receptor 1 (CMKLR1). Among the down 
regulated genes, Apolipoprotein L is downregulated 2 fold. This protein plays an 
important role in cholesterol transport and also affects the movement of lipids in the 
cytoplasm. It also allows the binding of lipids to organelles. 
 
 
Transcriptomic Versus Proteomic Analysis 
 
 The transcriptomic data from the oxLDL treatment, described in the previous 
chapter, was compared with the proteomic data obtained in this study. Precisely, the 
oxLDL induced gene expression data from microarrays that increased/decreased at least 
two folds after oxLDL treatments were compared with the list of proteome qualitative 
data. Among the 153 differentially expressed genes in transcriptome analysis, 22 were 
probed in the qualitative proteome data. The rest were not probed by proteomic analysis 
Similarly, among the 41 differentially expressed proteins in proteome analysis, all of 
them were probed in the transcriptome data (Table 5-3). Also, when differentially 
expressed genes were compared to differentially expressed proteins only two genes were 
common to both the list. HMOX1 is upregulated in both the transcriptome and proteome 
data whereas BICD1 is upregulated in transcriptome data and downregulated in proteome 
data. While the proteome data did not show comparable fold changes from oxLDL VS 
control groups as it had shown in transcriptome data, the trend of regulation was similar 
for most of the proteins. The very subtle changes seen in the proteome study may be due 
to the short incubation time that might not have given sufficient time for the changes in 
genes to translate into changes into proteins. This observation was similar to the 
observations reported by many other studies, i.e., they also compared the transcriptome 
data with corresponding proteome data from the same sample and under the same 
condition and couldn’t get a high correlation between the two [217-221]. Various other 
reasons could explain the discrepancy between the transcriptome data with the proteome 
data. First, the half-life of mRNA is less compared to protein half-life [222]. Moreover, 
various post-translational changes also result in the decreased half-life of the proteins 
[25] or even affect the steady-state level of protein in a given tissue at a particular time. 
Also, the unpredictability of mRNA expression level during cell cycle can affect the 
mRNA-protein correlation [223]. 
 
 There exists a study that compared the transcriptome and proteome changes in 
ARPE-19 cells due to photocoagulation. In this study, the authors measured the 
transcriptome at 2 h, 6 h, and 24 h, whereas proteome analysis was only done after 48 h. 
With the Still, the authors found only 24 common genes, out of more than 900 genes 
differentially expressed genes on microarray data that showed changes in proteome level 
[224]. This aligns with the very little correlation of transcriptome and proteome data in 
our samples as our analysis of proteome and transcriptome data was done at the same 
time point i.e.at 4 h.  
 
 We also analyzed our list of differentially expressed genes that were involved in 
the different molecular pathways described in chapter 4. Among the genes involved in 
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Table 5-3. List of common proteins/genes probed in microarray and proteomic 
studies. 
 
Gene Name UniProt ID Description 
HMOX1 P09601 Heme oxygenase 1  
CPT1A P50416 Carnitine O-palmitoyltransferase 1_ liver isoform  
CTGF P29279 Connective tissue growth factor  
EHD4 Q9H223 EH domain-containing protein 4  
ENO2 P09104 Gamma-enolase  
EPHA2 P29317;P29322;P54756 Ephrin type-A receptor  
EPHX1 P07099 Epoxide hydrolase 1  
FASN P49327 Fatty acid synthase  
HK2 P52789 Hexokinase-2  
HMGCS1 Q01581 Hydroxymethylglutaryl-CoA synthase_ cytoplasmic  
JAK2 O60674 Tyrosine-protein kinase JAK2  
LDLR Q14696 LDLR chaperone MESD  
LPCAT1 Q8NF37 Lysophosphatidylcholine acyltransferase 1  
MPP2 Q14168 MAGUK p55 subfamily member 2  
NQO1 P15559 NAD(P)H dehydrogenase [quinone] 1  
PCDH18 Q9HCL0 Protocadherin-18  
PHLPP1 O60346 PH domain leucine-rich repeat-containing protein phosphatase 1  
PLIN2 Q99541 Perilipin-2  
SLC3A2 P08195 4F2 cell-surface antigen heavy chain  
SPTLC2 O15270 Serine palmitoyltransferase 2  
TXNIP Q9H3M7 Thioredoxin-interacting protein  
CFAP52 Q8N1V2 Cilia- and flagella-associated protein  
TGM1 P22735 Protein-glutamine gamma-glutamyltransferase K  
14-Sep Q6ZU15 Septin-14  
MYO19 Q96H55 Unconventional myosin-XIX  
PDCD10 Q9BUL8 Programmed cell death protein 10  
RARRES2 Q99969 Retinoic acid receptor responder protein 2  
CCNI Q14094 Cyclin-I  
CCDC150 Q8NCX0 Coiled-coil domain-containing protein 150 
MYO5B Q9ULV0 Unconventional myosin-Vb  
SULT2A1 Q06520 Bile salt sulfotransferase  
GALNS P34059 N-acetylgalactosamine-6-sulfatase  
ABCB7 O75027 ATP-binding cassette sub-family B member 7_ mitochondrial  
MCM2 P49736 DNA replication licensing factor MCM2  
RPS10 P46783 40S ribosomal protein S10  
NAGLU P54802 Alpha-N-acetylglucosaminidase  
PPP3CA Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha 
GNL3 Q9BVP2 Guanine nucleotide-binding protein-like 3 
CARHSP1 Q9Y2V2 Calcium-regulated heat-stable protein 1  
ZMPSTE24 O75844 CAAX prenyl protease 1 homolog  
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Table 5-3. (Continued.) 
 
Gene Name UniProt ID Description 
PIN1 Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1  
SOGA3 Q5TF21 Protein SOGA3  
SLC12A2 P55011 Solute carrier family 12 member 2  
FAM69A Q5T7M9 Protein FAM69A  
BICD1 Q96G01 Protein bicaudal D homolog 1  
IQCE Q6IPM2 IQ domain-containing protein E  
SDC1 P18827 Syndecan-1  
GOLPH3 Q9H4A6 Golgi phosphoprotein 3  
APOL2 Q9BQE5 Apolipoprotein L2  
ZC3H13 Q5T200 Zinc finger CCCH domain-containing protein 13  
TET1 Q8NFU7 Methylcytosine dioxygenase TET1  
FBF1 Q8TES7 Fas-binding factor 1  
ACBD3 Q9H3P7 Golgi resident protein GCP60  
NFS1 Q9Y697 Cysteine desulfurase_ mitochondrial  
C3orf58 Q8NDZ4 Deleted in autism protein 1  
RPL37A P61513;A6NKH3 60S ribosomal protein L37a  
ZW10 O43264 Centromere/kinetochore protein zw10 homolog  
MCF2L2 Q86YR7 Probable guanine nucleotide exchange factor MCF2L2  
FAM84B Q96KN1 Protein FAM84B  
WDFY1 Q8IWB7 WD repeat and FYVE domain-containing protein 1  





anti-oxidative mechanism, lipid metabolism, autophagy and circadian rhythm eight genes 
were probed in qualitative proteome list: HMOX1, FASN, HMGCS1, LDLR, NQO1, 
PHLPP1, SPTLC2, and TXNIP. The proteins involved in oxidative stress are HMOX1, 
TXNIP and NQO1, similarly proteins involved in lipid metabolism were LDLR, 
HMGCS1, FASN and SPTLC2. Only gene involved in circadian rhythm was identified in 





 Mass spectrometry based proteomics has been a work horse for discovery-based 
research in the field of proteomics. The development of new hybrid instruments and 
various sample preparation and separation techniques along with data acquisition 
methods has fundamentally changed the way scientists interrogate biological systems. 
The MS based proteomics has outstanding ability to investigate thousands of proteins 
along with post translational modification qualitatively and quantitatively.  
 
 In our study, we utilized a bioanalytical platform that included nano-UPLC along 
with state-of-art mass spectrometer to investigate the proteome of ARPE-19 cells. We 
also interrogated oxLDL mediated differential proteome alteration in ARPE-19 cells., the 
first study of its kind in the literature. The use of nano UPLC increased separation 
efficiency, improved resolution, decreased the analysis time and lowered the operating 
cost when compared to the nano HPLC used in our previous study (Chapter 2). Higher 
chromatographic separation and mass resolution provided high coverage and mass 
spectral data quality. High quality of mass spectral data is necessary for quantitative 
analysis. The current bioanalytical platform outperformed the bioanalytical platform 
discussed in chapter 2 in terms of proteome coverage. The new platform was able to 
identify 3-fold more proteins compared to the best described in chapter 2. Moreover, the 
ARPE-19 protein panel encompassed proteins with various functional roles including 
macromolecular degradation and anti-oxidant activity and junctional proteins. The 
bioanalytical platform used in this study utilized data independent acquisition (DIA) 
method which allowed the fragmentation and identification of all the peptides that eluted 
at a given point in gradient elution. Hence, it provided unbiased identification and label 
free quantification of protein in the oxLDL treated and untreated samples.  
 
 Interestingly, there was very little correlation between the 4 h transcriptome and 
proteome data as seen by various other studies. This study provides the foundation of a 
bioanalytical platform for identifying the RPE proteome. The list of differentially 
expressed proteins due to oxLDL treatment identified in this study gives insight to the 




CHAPTER 6.    CONCLUSION AND FUTURE DIRECTIONS 
 
 
 Mass spectrometry based proteomics is an important component of biological 
research today as it allows identification, quantification, and characterization of proteins 
to better understand the complex biological pathways and protein-protein interactions 
undergoing within the cells. Both data-dependent and data-independent mass 
spectrometry based approaches are continuously being optimized and improved which 
enable scientists in obtaining finest results in terms of the desired outcome. 
 
 Towards the data-dependent approach in mass spectrometry, we presented a 
bioanalytical platform, a bottom-up approach that was able to provide better coverage 
and identification of proteins in a biological system. Three different bio-analytical 
platforms that utilized IEF, SDS-PAGE, and RP-RP as pre-fractionation methods before 
LC-MS/MS analysis were evaluated. Among the three platforms that were used in our 
study, the SDS-PAGE-LC-MS/MS was superior to the IEF and RP-RP separation in 
terms of in-depth protein coverage. We also leveraged the data-independent approach for 
data acquisition on a high-resolution mass spectrometry, a more recent method in bottom 
up proteomics, to identify and quantify protein profile in ARPE-19 cells. On this regard, 
we showed that the use of high-resolution mass spectrometry even without the 
fractionation provides the higher number of protein identification and label-free 
quantification. The use of nano-UPLC, high-resolution instrument and data independent 
acquisition method alone increased the protein identification from 980 protein obtained 
from pre-fractionation of samples to ca. 3000 proteins without fractionation. In addition 
to proteome profiling, the bioanalytical platform was able to identify proteins with 
various functional roles. 
 
 Both the proteomics and transcriptomic based application approaches were 
applied to understand the oxidized lipoproteins- induced changes in the ARPE-19 cells to 
better understand the molecular mechanism that may be contributing to development of 
AMD, which is the leading cause of blindness in the western world. The transcriptome 
analysis of early events showed the involvement of Nrf-2 mediated pathways and the 
induction of anti-oxidative pathways to protect the cells from the oxidative damage. In 
addition to the induction of genes involved in the protection of cells against the oxidative 
stress the study also showed the downregulation of genes involved in lipoprotein uptake 
and cholesterol biosynthesis. One of the novel pathways discovered in our studies is the 
circadian rhythm pathways. The genes involved in circadian rhythm were down-regulated 
due to oxLDL treatment for four hours. In an analogous study to the transcriptome 
analysis, we performed proteome analysis of the oxLDL induced changes in ARPE-19 
cells which also showed the upregulation of anti-oxidant HMOX1 similar to the 
transcriptome results. However, the amount and extent of change that we saw in the 
transcriptome did not translate to the proteome as indicated by many other studies [147-
149]. For future continuation of this study, bioanalytical and biological considerations 
can be made. To obtain better correlation between transcriptome and proteome data, it 
would be interesting to see the effect of using of extra-long gradients with/without pre-
fractionation prior to LC-MS/MS analysis. For biological consideration longer oxLDL 
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exposures can be done to get mechanistic understanding of the differentially expressed 
proteins.  
 
 Accumulated oxidized lipids play a crucial role in the development of AMD 
which are identified by scavenger receptors present in the RPE cells. The scavenger 
receptors aid in clearance of oxidized lipids by these cells. In our study, we studied the 
role of scavenger receptors CD36 and CD5L/AIM in oxLDL uptake by ARPE-19 cells. 
The scavenger receptor CD5L/AIM was recently identified as an increased autoantigen in 
the diseased population by our group. We demonstrated that ARPE-19 cells internalize 
oxLDL which was primarily dependent on CD36 because the use of SSO which binds 
with CD36 significantly decreased the uptake of oxLDL in the cells. We also 
demonstrated that oxLDL does bind to CD5L/AIM by ELISA and also in-vivo by live 
imaging with CD5L/AIM transfected cells. Moreover, the CD5L/AIM and CD36 were 
seen to co-localize in the presence of oxLDL. However, our results did not show the 
change in CD5L/AIM and CD36 in the transcript or in the protein level after 4 hours of 
oxLDL treatment. The use of anti- CD5L/AIM antibody did show a reduction of the 
amount of intracellular oxLDL in the ARPE-19 cells which was, however, not significant 
when compared with the isotype control. Therefore, to see the effect of adding external 
CD5L/AIM on the oxLDL clearance by the cells, we incubated the cells with DiI-oxLDL 
in the presence of rhCD5L/AIM. This study, which involved measurement of 
intracellular oxLDL at a single time point (after 5h of oxLDL exposure) showed a 
significant reduction of the accumulation of intracellular oxLDL in ARPE-19 cells. 
 
 The reduction in intracellular accumulation of oxLDL due to extracellular 
recombinant CD5L/AIM is an interesting phenomenon as it has been recently shown the 
involvement of CD5L in autophagy. It would be interesting to know how the CD5L/AIM 
works in reducing accumulation of oxLDL in the cells. Does CD5L/AIM block the 
uptake of oxLDL by itself or does it aid in early clearance of oxLDL by ARPE-19 cells? 
Answers to these questions would elucidate the innovative role of CD5L/AIM in oxLDL 
clearance in the eye. For this, the use of the antibody that could bind to the rhCD5L or 
IgM which is known to bind to the CD5L/AIM could elucidate the mechanism. 
Moreover, a study of intracellular oxLDL accumulation over multiple exposure times 
would shed more light into the dynamics of oxLDL degradation by the cells and help 
understand the role of CD5L/AIM in this process.  Finally, to understand the involvement 
of CD5L/AIM in autophagy-related processes the use of autophagy inhibitor along with 
rh CD5L/AIM would validate the role of rh CD5L/AIM in intracellular oxLDL clearance 
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